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        The dopamine transporter (DAT) mediates reuptake of dopamine from the synaptic cleft 
into the presynaptic terminus and plays a critical role in maintaining the normal function of 
dopaminergic neurons. DAT is the major target of widely abused psychostimulant drugs, 
including cocaine and amphetamine. DAT also figures into disease states, and it is a target for 
therapeutic drugs. It is known that cathinone and methcathinone, β-keto analogs of amphetamine 
and methamphetamine, respectively, produce pharmacological actions similar to amphetamine.     
        Cathinone and methcathinone analogs are recently gaining in popularity on the 
clandestine market (e.g. ‘bath salts’). Cathinone and methcathinone analogs as well as their
xiii 
 
 
 
amphetamine and methamphetamine counterparts were synthesized and examined at the hDAT 
expressed in Xenopus oocytes. One of the two major constituents of ‘bath salts’ (i.e., 
mephedrone) produced an electrophysiological signature similar to the dopamine releasing agent 
S(+)-amphetamine while the other major constituent (i.e., MDPV) produced an 
electrophysiological signature similar to the dopamine re-uptake inhibitor cocaine. 
  
1 
 
I. Introduction 
 
 
 
        Khat (Catha edulis, Celestraceae) is a plant, indigenous to the Arabian Peninsula and 
tropical East Africa. The fresh leaves of the khat plant have been brewed as a ‘tea’ or chewed for 
their central stimulant properties in the Arabian Peninsula and in certain regions of eastern 
Africa. Cathinone was determined to be an active constituent of khat. Racemic cathinone and its 
individual optical isomers were found to have pharmacological actions similar to amphetamine. 
Methcathinone, the N-methyl analog of cathinone, was investigated by Glennon and co-workers. 
It was found that cathinone and methcathinone produced discriminative stimulus effects similar 
to S(+)-amphetamine in rats. The studies also showed that amphetamine, methamphetamine, 
cathinone and methcathinone produced similar locomotor stimulation in mice. 
        There are number of new synthetic analogs of cathinone and methcathinone gaining in 
popularity on the clandestine market and have created considerable attention. Although, 
cathinone and methcathinone are controlled substances, most of their analogs are not. One of the 
more popular synthetic cathinones is a combination known as ‘bath salts’ which contains 
mephedrone and methylenedioxypyrovalerone. The major constituents of ‘bath salts’ were 
recently scheduled (Schedule I). However, very limited data are available regarding the 
pharmacology and mechanism of action of cathinone and methcathinone analogs. Therefore, 
there is need for investigation in this area 
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        Dopamine (DA) is involved in the control of numerous functions including locomotor 
activity, reward mechanisms, cognition and neuroendocrine functions. In addition, the 
dysfunction of DA system in CNS is related to a broad spectrum of neuropsychiatric disorders, 
such as Parkinson’s disease, schizophrenia, Tourette’s syndrome, attention-deficit hyperactivity 
disorder, and drug addiction. The dopamine transporter (DAT) mediates reuptake of dopamine 
from the synaptic cleft into the pre-synaptic nerve terminus and thereby plays a critical role in 
terminating dopaminergic signaling and in maintaining a releasable pool of dopamine. 
Amphetamine-like psychostimulant drugs cause a drastic increase in synaptic DA levels by 
reverse transport and/or channel-like activity of the DAT. 
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II. Background 
 
 
 
A. Amphetamine-like CNS Stimulants: 
1. Overview: 
        Simple arylalkylamines (AAAs) are known to have widespread abuse potential. 
Arylalkylamines are further subdivided into the indolealkylamine (IAAs) and the 
phenylalkylamines (PAAs).
1
 The phenylalkylamines can be further subdivided into the 
phenylethylamines and phenylisopropylamines. Amphetamine (AMPH, 1) is the prototypical 
central stimulant of the phenylisopropylamine class.
1
 
 
 
 
        The synthesis of amphetamine was first reported in 1931 and 1932 by Hartung and Munch
2
 
and Alles,
3
 respectively. The pressor effects of amphetamine were explained by Piness and 
coworkers.
4
 Amphetamine, due to its ability to promote wakefulness and vigilance, was used in 
the treatment of narcolepsy.
5
 After some time, a study demonstrated that benzedrine (racemic or 
  
4 
 
dl-AMPH) administration could improve the academic performance of children with behavioral 
disorder.
6
  
        This created a foundation for the usefulness of psychostimulants to treat attention-deficit 
hyperactivity disorder.
7
 Amphetamine has also been used to treat fatigue, obesity, Parkinsonism 
and for the reversal of CNS depressant toxicity.
8
 Amphetamine has both peripheral and central 
effects.
8
 Oral administration of amphetamine increases systolic and diastolic blood pressure in 
humans and animals.
8
 It leads to decreased heart rate, and cardiac arrhythmias may result after 
large doses.
8
 As with other sympathomimetic agents, smooth muscle reacts to amphetamine.
8
 
Amphetamine causes relaxation of bronchial muscle, while it contracts the urinary bladder 
sphincter.
8
 In the periphery, the (-)-isomer of amphetamine is equiactive or slightly more potent 
than its enantiomer.
8
 Peripheral effects of amphetamine include mydriasis, tremor, sweating, jaw 
clenching, dry mouth and restlessness.
9
 These actions may be mediated through the release of 
norepinephrine, causing indirect sympathomimetic stimulation.
9
 
        Amphetamine, a psychostimulant, causes increased alertness, wakefulness, insomnia, 
energy and self-confidence in addition to decreased fatigue and appetite, as well as also 
enhancing mood, well-being and producing euphoria.
10,11
 High doses lead to convulsions, 
stereotypic movements and psychosis.
10,11
 When the effect of amphetamine fades, fatigue, 
anxiety and tiredness can be seen.
10,11
 These undesirable symptoms (‘crash’) are seen more when 
high or repeated doses are administered, and depression and lethargy can occur.
9
 Long term 
amphetamine use may lead to development of a so called ‘amphetamine psychosis’ characterized 
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by psychotic reactions, hallucinations and paranoia.
9
 Amphetamine has high abuse potential and 
can induce dependence, tolerance and withdrawal symptoms.
9
 
        Amphetamine has been used as anorectic drug, but it appears to cause unacceptable 
tachycardia and hypertension.
12
 Because amphetamine has high abuse potential, it does not have 
US Food and Drug administration indication for the treatment of obesity.
12
 It was found that in 
humans weight loss is due to decreased food intake and not to increased metabolism.
8
 Drug 
induced acute loss of smell and taste have been described; however, dietary restriction is 
important for successful weight loss.
8
 The anorectic action of amphetamine has been reported 
due to the activation of dopaminergic and/or β-adrenergic receptors within the perifornical 
hypothalamus.
13
 
        Additional physiological responses of amphetamine in humans and animals have been 
reported as amphetamine-induced hypothermia due to a decrease in metabolic heat production.
14
 
However, at high ambient temperatures, amphetamine induces hyperthermia, which is through 
the increase in metabolic rate due to behavioral excitation and cutaneous vasoconstriction.
8,14
 
        Amphetamine-induced acute toxic effects are related to its pharmacological actions.
15 
Amphetamine anorectic activity has been related to an increased risk of pulmonary 
hypertension.
16 
Symptoms of mild toxicity include nausea, vomiting, mydriasis, dry mouth, 
sweating, hyperreflexia, bruxism, trismus and palpitations.
17
 Moderate intoxication by 
amphetamine can include hyperactivity, anxiety, confusion, panic attack, psychosis with 
hallucinations, tachycardia, hypertension and increased body temperature.
17
 Sometimes suicidal 
and homicidal tendencies can occur.
17
 Severe intoxication by amphetamine includes delirium, 
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coma, seizures, hypertension, dysrhythmia, hyperpyrexia, and renal failure associated with 
rhabdomyolysis. Additionally, amphetamine can induce acute ischaemia and haemorrhagic 
stroke.
17 
 
2. General Structure-activity relationship (SAR): 
        Most phenylisopropylamine derivatives lack central stimulant activity.
18
 In general, there 
are more “non-amphetamine like” derivatives of amphetamine than “amphetamine like” 
derivatives of amphetamine.
18
 That is, comparatively few amphetamine derivatives retain the 
central stimulant action of amphetamine (1), still fewer retain the potency of amphetamine.
18
 
        The central stimulant action of amphetamine and amphetamine-related agents is commonly 
assessed by measuring their ability to increase the locomotor activity of rodents. That is, these 
agents are locomotor stimulants and produce hyperlocomotion. Another means of measuring the 
“amphetamine-like” nature of central stimulants is to examine their stimulus properties in 
animals trained to discriminate amphetamine, an amphetamine isomer, or a related agent, from 
saline vehicle. In this procedure, animals are generally trained to distinguished (i.e., 
discriminate) among the effects produced by one drug to those produced by another. Another 
drug, which compares to test drug, may be a different drug, a different dose of the test drug or 
vehicle. Studies can be done, when the animals learned to discriminate the training drug from, 
for example, vehicle (saline). 
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         These two measures provide comparable results and offer a convenient approach to 
formulation of structure-activity relationships. Using data from such assays, it is relatively easy 
to determine the effect of structure modification on amphetamine-like activity.  
 
a.  N-Alkylated substituents: 
        The primary aim of structure-activity studies are to identify those structural features of an 
agent that are necessary for or that contribute to activity. It was reported by Woolverton in self-
administration studies of test drugs in cocaine-maintained animals that N-alkylated amphetamine 
having substituent groups larger than ethyl are less potent behaviorally than N-methyl (i.e., 2) 
and N-ethyl (i.e., 3) substituted amphetamine derivatives and it may be due to decreased ability 
of those compounds to release catecholamines centrally.
19
 It was reported that methamphetamine 
(2) produces stimulus generalization to (+)-amphetamine.
20
 Van der Schoot et al.
21
 found that 
homologation of the N-methyl group of (±)-methamphetamine to ethyl, n-propyl, and n-butyl, 
resulted in a rapid decrease in a mouse locomotor activity assay. 
 
 b. α-Alkyl substituents: 
         The methyl group present alpha to the amino group in amphetamine has been previously 
established to hinder metabolism by monoamine oxidase by a steric effect.
8
 The methyl group 
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also makes amphetamine optically active.
22
 The both enantiomers of amphetamine have been 
examined.
22
 As behavioral stimulants and as releasers of striatal DA, the (+)-isomer of 
amphetamine is 5-7 times more potent than the (-)-isomer; however, the (-)-isomer was found to 
be equipotent to the (+)-isomer for the release of NE and is similar in potency for the 
development of acute psychotic symptoms in humans.
22
 It is reported that with respect to 
peripheral actions, both enantiomers of amphetamine are essentially equivalent in potency, while 
the (+)-isomer of amphetamine is seven-fold more active than the (-)-isomer in producing central 
effects.
23
 As both optical isomers of amphetamine produce a similar discriminative stimulus 
effect but that one isomer is fairly more potent than the other, Young et al.
23
 referred to 
amphetamine as being stereoselective rather than stereospecific. The removal of the α-methyl 
group results in a compound (PEA, phenylethylamine) which does not produce amphetamine-
stimulus generalization in animals.
23
 
        At the α-position of amphetamine, extension of the methyl to an ethyl group dramatically 
reduces amphetamine-like activity.
24
 It has been reported that the (+)-α-ethyl homolog of 
amphetamine (i.e., 4) failed to fully substitute for 1 mg/kg of amphetamine in drug 
discrimination studies in rats.
24
 In the same study, the (±)-α-ethyl homolog of N-
methylamphetamine (i.e., 5) was able to substitute to amphetamine but showed one-tenth the 
potency of amphetamine.
24
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c. Aromatic substituents: 
 
        The introduction of para-chloro substitution (i.e., 6) in the aromatic portion of amphetamine 
failed to produce stimulus generalization in drug discrimination studies in rats trained to 
discriminate amphetamine from saline, while in the same studies para-fluoro substitution (i.e., 7) 
produced stimulus generalization.
25
 The benzene ring fusion of the b-face (i.e., 1-NAP, 1-
naphthyl analog of amphetamine, 8) or the c-face (i.e., 2-NAP, 2-naphthyl analog of 
amphetamine, 9) of racemic amphetamine failed to produce stimulus generalization in drug 
discrimination studies in rats trained to discriminate amphetamine from saline.
23
 These two 
naphthyl analogs were inactive as locomotor stimulants in mice.
21 
         Amphetamine analogs resulting from aromatic substitution are, in general, not 
amphetamine-like.
23
 It was demonstrated by several groups that the 4-hydroxy analog of racemic 
amphetamine (i.e., 4-OH PIA, 10) does not produce amphetamine-appropriate responding,
26-28
 
and was inactive in mouse locomotor assays.
21
 Probably, this is because of the inability of 4-OH 
PIA to penetrate the blood-brain barrier.
23
 O-Methylation of 4-OH PIA results in a less polar 
compound, i.e., 4-methoxyamphetamine (PMA, 11).
28,29
 In two separate studies, it was found 
that PMA produces amphetamine-stimulus generalization, but is less potent than 
amphetamine.
28,29
 PMA was only a weak locomotor stimulant in mice.
21,30 
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        The 3,4-methylenedioxy analogs of amphetamine and methamphetamine (MDA, 12 and 
MDMA, 13, respectively) have been studied.
31
 It was found that racemic MDA and MDMA 
produce amphetamine-like stimulus effect in rats trained to discriminate amphetamine from 
saline.
31
 However, in the same study, S(+)-MDA produced amphetamine-like effects while R(-)-
MDA failed to do so.
31
 
  
        The six possible dimethoxy analogs (DMAs) of amphetamine have been evaluated in 
amphetamine trained animals.
28
 It was found that none of these analogs produced complete 
amphetamine-stimulus generalization.
28
 Five possible trimethoxy analogs (TMA’s) of 
amphetamine (i.e. 2,3,4-TMA, 2,3,5-TMA, 2,4,5-TMA, 2,4,6-TMA, 3,4,5-TMA) have been 
studied.
28
 2,3,4-TMA and 2,3,5-TMA produced saline-like effects, while the other three analogs 
produced disruption of behavior.
23
 Two of the DMA (i.e., 2,4-DMA and 2,5-DMA) and all TMA 
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derivatives of amphetamine were found to produce DOM like hallucinogenic effect in drug 
discrimination study.
32
 
        Methyl group substitution on the aromatic ring portion of amphetamine results in three 
possible methylamphetamines (or tolylaminopropanes; TAPs); i.e., oTAP, mTAP, and pTAP 
(14, 15 and 16, respectively). Only oTAP produced amphetamine-like stimulus effects in rats 
trained to discriminate (+)-amphetamine from saline, while mTAP and pTAP produced partial 
amphetamine-like stimulus effect in the same studies.
33
 Compounds 14 and 15 were found to be 
weak locomotor stimulants in the mouse.
21 
 
        Wee et al.
34
 reported the in-vitro potency of p-methylamphetamine (pTAP, 16) and p-
fluoroamphetamine (7) as releasers of monoamine neurotransmitters (Table 1). They also 
reported that as these compounds have the reinforcing effects consistent with full or partial 
amphetamine-like discriminative stimulus effects, pTAP and p-fluoroamphetamine have 
amphetamine type abuse potential.
34
 It has been also reported that p-methoxyamphetamine 
(PMA, 11) releases dopamine and norepinephrine (Table 1).
35
 PMA has been known to be used 
illicitly in Australia since 1994 and is also becoming popular at rave parties in the United 
States.
36
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     Table 1. In vitro potency of 4-substituted amphetamine analogs as releasers of monoamine 
neurotransmitters.
34,35 
Drug [
3
H] NE 
EC50(nM) 
[
3
H] DA 
EC50(nM) 
[
3
H] 5-HT 
EC50(nM) 
p-Methylamphetamine (pTAP; 16) 22.2 44.1 53.4 
p-Fluoroamphetamine (7) 28.0 51.5         939 
p-Methoxyamphetamine (11)        166            867 – 
 
d. Conformational constraint: 
        The side chain conformations of various phenylisopropylamines have been studied by 
nuclear magnetic resonance, and suggest that in solution, an extended trans-phenylamino 
arrangement is preferred.
29
 Some of the conformationally restricted analogs of 
phenylalkylamines mimic this conformation.
29
 For example 2-aminotetralin (2-AT, 17) mimics 
this to some extent, while 2-aminoindane (2-AI, 18) to a lesser extent. It was found that 2-AI 
(18) and in particular 2-AT (17) are capable of producing various amphetamine-like effects, 
including anorexia and locomotor stimulation in animals.
29
 Four conformationally restricted 
analogs, 2-AI (18), 2-AT (17), 6-amino- and 7-amino-6,7,8,9-tetrahydro-5H-benzocycloheptene 
(6-AB, 19 and 7-AB, 20, respectively) were studied and it was found that 2-AT (17) is most 
similar to racemic amphetamine in potency and may be the conformation that best mimics 
amphetamine necessary for producing amphetamine-like stimulant effects, however, compounds 
19 and 20 failed to produce amphetamine-like stimulant effect.
29
 The racemic aminotetralin 17 
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produced 10% the locomotor stimulant action of amphetamine in mice, whereas 18 was inactive 
at the highest doses tested.
21 
 
e. β-Substituents: 
        Substituents β to the amine have not been well explored.20 Ephedrine (21), an agent that 
possesses a β-hydroxy group was found to produce amphetamine-stimulus generalization.20 In 
animals, administration of norephedrine (22) produced 70-75% amphetamine-appropriate 
responding.
20
 
 
        The β-keto analog of amphetamine, i.e., cathinone (23), is a central stimulant that occurs 
naturally.
29,37
 There is little effect of this carbonyl group on potency.
29,37
 Cathinone was found to 
produce amphetamine-like responding and also like amphetamine, the S-isomer of cathinone is 
more potent than the R-isomer.
29,37
 Cathinone and its derivatives are discussed in more detail in a 
later section. 
        The general structure-activity relationships for amphetamine-like action are summarized in 
Figure 1. 
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Figure 1. General structure-activity requirements for producing amphetamine-like central 
stimulant and/or discriminative stimulus effects  
 
A. N-alkyl substituents: 
     -NHCH3 > -NH2 > -NHR (R except CH3) 
B. Chiral center: 
     S(+)-isomer is more potent than R(-)-isomer 
C. α-Methyl substituent: 
     Optimal; removal or extension from methyl reduces potency 
D. β-substituents: 
    =O ≥ -H ≥ -OH 
E. Aromatic substituents: 
    Generally reduce potency  
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3. Mechanism of Action:  
        Amphetamine acts as an indirect monoamine agonist, producing release of norepinephrine, 
dopamine and serotonin from presynaptic terminals in the CNS and at the peripheral levels.
38,39
 
Similar results have been reported by Rothman et al.
40
 in invitro studies (Table 2).  
 
Table 2. Pharmacological profile of amphetamine in DA, NE, and 5-HT release and uptake 
inhibition assays.
40
 
Drug 
NE Release 
EC50 
(nM) 
NE Uptake 
Ki 
(nM) 
5-HT Release 
EC50 
(nM) 
5-HT Uptake 
Ki 
(nM) 
DA Release 
EC50 
(nM) 
DA Uptake 
Ki 
(nM) 
S(+) - Amphetamine   7.07  38.9  1765  3830  24.8    34  
S(+) - Methamphetamine 12.3  48.0    736  2137 24.5  114  
 
        Amphetamine interacts with the membrane transporters responsible for neurotransmitter 
reuptake and vesicular storage systems.
17
 It looks like amphetamine is able to enter the nerve 
terminal through passive transport or through a reuptake transporter, thus inhibiting the reuptake 
of monoamines.
17
 Once transported inside the neuron, amphetamine reverses the direction of the 
transporter causing it to release norepinephrine, dopamine and serotonin to the synaptic cleft.
17
 
Its exact mechanism for producing these effects is unknown. However, an alternative mechanism 
explained by De Felice and co-workers, once amphetamine is inside the terminal.
41
 In addition, 
amphetamine is also found to act as a mild inhibitor of the enzymes monoamine oxidase A and 
B.
17
 However, there does not seen to be a relationship between the locomotor actions of these 
agents and inhibition of MAO.
21 
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        The anorectic effect, alerting effect and a part of the locomotor-stimulating action of 
amphetamine are presumably through release of NE and DA from noradrenergic nerve 
terminals.
8
 Treatment of the animals with α-methyltyrosine, an inhibitor of tyrosine hydroxylase, 
prevents all these effects of amphetamine by inhibiting catecholamine synthesis.
8
 Particularly in 
the neostriatum, release of DA from dopaminergic nerve terminals by amphetamine has been 
linked to certain aspects of locomotor activity and stereotyped behavior.
8
 These behavioral 
effects are seen at higher doses, and it can be understood by the need of higher concentration of 
amphetamine to release DA from brain slices or synaptosomes in vitro.
8
 
        Depletion of serotonin by pretreatment of animals with para-chlorophenylalanine (oral or 
intraperitoneal administration) trained to discriminate amphetamine from saline had no 
significant effect on amphetamine-appropriate responding.
42
 Similarly, there was no effect when 
animals pre-treated with disulfiram,
42
 phenoxybenzamine,
42
 phentolamine,
43
 atropine
43 
and 
propranolol.
42,44,45
 Ho and Huang,
44
 based on the results gained with α-methyl-para-tyrosine 
suggested that dopamine might play dominant role in the discriminative stimulus produced by 
amphetamine; they also suggested that the stimulus generated by amphetamine might be more 
dependent on newly formed dopamine rather than direct interaction of amphetamine with 
dopamine receptors. It was found that the dopamine precursor L-DOPA (in combination with a 
decarboxylase inhibitor) produced amphetamine-stimulus generalization.
23
 From the majority of 
studies, it was found that apomorphine can produce an effect that is somewhat similar in nature 
to that produced by amphetamine.
23
 This result supports the suggestion made by Ho and Huang, 
that a direct dopamine interaction may not be as important as the release of newly synthesized 
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dopamine in producing amphetamine stimulus.
23,44
 Further, D’Mello has suggested that 
mesolimbic dopamine system may play a role in the amphetamine discriminative stimulus, based 
on electrical brain-stimulation experiments.
46
 
        It has been suggested by McMillen that behavioral stimulants can be sub-divided into two 
classes of drugs: 1. amphetamine-like direct releasers, and 2. up-take blockers, of dopamine and 
norepinephrine.
23
 Amphetamine-like agents release directly, as well as inhibit reuptake of 
dopamine and norepinephrine in both invivo and invitro studies.
23
 Additional studies were done 
with antagonists of particular neurotransmitters to study discriminative stimuli mechanism.
23
 All 
attempts to abolish or attenuate the amphetamine stimulus effects by pretreatment of animals 
with serotonin antagonists have been unsuccessful.
23
 Similarly, tricyclic antidepressants, e.g. 
imipramine, nortryptiline, desipramine, failed to block an amphetamine stimulus.
47
 Supporting 
the belief that the stimulus effects of amphetamine are mediated through a dopaminergic 
mechanism, certain dopamine antagonists have been found to attenuate amphetamine appropriate 
responding; e.g. chlorpromazine,
44,47
 clozapine,
48
 pimozide,
44
 trifluperazine,
47,49
 thioridazine,
47
 
fluphenazine,
49
 and haloperidol.
42,45,49-51
 Thus, it appears that amphetamine is producing 
discriminative stimulus, most likely centrally mediated, through a mechanism that involves 
dopamine and to a lesser extent norepinephrine.
23
 
        It has been reported that chronic misuse of amphetamine may result in long-lasting 
impairment of brain function.
52
 Neurochemical and morphological changes in dopamine or 
serotonin neurons in animal studies with response to administration of amphetamine have been 
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partially confirmed with brain imaging studies in humans (reduction in dopamine/serotonin 
transporters).
53-60
 
        Methamphetamine produces euphoria by elevating synaptic dopamine.
61,62
 
Methamphetamine, being lipophilic, may enter nerve terminals by diffusing across the plasma 
membrane.
61,62
 Inside the terminal, methamphetamine binds to the dopamine transporter (see 
Table 2) to prevent reuptake and also induces the release of dopamine into the synapse.
61,62
 
Methamphetamine increases dopamine in the cytoplasm which causes neurotoxicity.
61,62
 
Methamphetamine produces these effects via increasing cytoplasmic dopamine through 
promoting the activity of tyrosine hydroxylase (which increases dopamine production) and 
inhibiting monoamine oxidase (which metabolizes dopamine), while the dominant mechanism is 
the effect of methamphetamine on the dopamine transporter, VMAT-2. The combined action of 
methamphetamine leads to increased concentration of cytoplasmic and synaptic dopamine.
63-71
 
        Methamphetamine, apart from binding to the dopamine transporter and preventing reuptake 
of dopamine from the synapse, also reverses the dopamine transporter direction causing the 
transporter to release dopamine from the cytoplasm into the synapse.
72
 The mechanism of this 
phenomenon is unknown.
72
 After 1 h post ingestion, methamphetamine decreases the function of 
the vesicular dopamine reuptake transporter.
61
 The vesicular dopamine transporter normalizes 
within 24 h following the ingestion of a single dose of methamphetamine, but after multiple high 
doses of methamphetamine, vesicular dopamine transporters only normalize partially.
61
 
        In postmortem studies using positron emission tomography (PET), the chronic 
methamphetamine use decreases dopamine transporter density in certain regions of brain 
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associated with motor and cognitive impairment.
72
 Though after prolonged drug abstinence, 
dopamine transporter density may slowly return to normal, implying that the decrease in 
transporter density at the beginning is a neuroadaptive response to the increased synaptic 
dopamine.
72
 While, even if dopamine transporter density returns to normal after drug abstinence, 
cognitive deficits may still persist.
72
  
        In human methamphetamine users, PET studies show decreased D2 receptor density that 
may be due to down-regulation from exposure to increased synaptic dopamine concentrations.
73
 
A redistribution of VMAT-2 due to methamphetamine within the nerve terminal is seen, which 
makes the transporter less available to the dopamine molecule, reducing the ability of 
cytoplasmic dopamine to move into the protective vesicle.
72
 In addition, methamphetamine also 
leads to release of dopamine from the vesicle into the cytoplasm by two methods.
66-69
 First, 
binding of methamphetamine to VMAT-2 causes vesicular dopamine efflux into the 
cytoplasm.
66-69
 Second, amphetamine, being a weak base, moves across the vesicular membrane 
in its unchanged form and accumulates in the acidic vesicle in its charged form (now less able to 
penetrate the vesicle membrane).
66-69
 The acidic pH gradient inside the vesicle provides the 
energy for amphetamine accumulation in the vesicle against its concentration gradient.
66-69
 As 
more and more basic amphetamine accumulates into vesicles, the interior of the vesicle becomes 
more alkaline.
66-69
 Due to this alkalinization, the vesicle collapses releasing dopamine into the 
cytoplasm.
66-69
 
        As vesicular dopamine decreases, it also causes a decrease in dopamine release into the 
synapse following depolarization.
61
 However, the overall concentration of synaptic dopamine 
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depends on the action of methamphetamine on the dopamine transporter.
61
 Methamphetamine 
produces selective degeneration of dopamine neuron terminals without cell body loss in neuronal 
cell cultures.
74
 Methamphetamine acidotropic uptake causes osmotic swelling of vacuoles.
74
 
Hyperthermia and oxidative stress may be seen at the initial stage of methamphetamine 
neurotoxicity.
74
 
        Acidic organelles, like synaptic vesicles, are collapsed by methamphetamine-induced 
release of dopamine into the cytoplasm.
72
 In the cytoplasm, dopamine reacts with molecular 
oxygen to form reactive oxygen species (ROS) such as superoxide- and hydroxyl-free radicals 
and hydrogen peroxide.
72
 This whole process is known as intracellular oxidative stress.
72
 These 
ROS lead to damage all cellular biomacromolecules (lipids, sugar, proteins, polynucleotides) and 
can also form secondary products that cause damage as well.
72
 The CNS is more susceptible to 
oxidative insult due to high concentration of polysaturated lipids and redox-active transition 
metals, as well as poor concentration of antioxidant and high rates of oxygen utilization.
72
 The 
neurotoxic effects seen in animals after methamphetamine administration might be due to 
oxidative stress.
72
 
        The original dopamine hypothesis of schizophrenia proposed that there is overactivity of the 
striatal dopamine systems.
75
 Additionally, antipsychotic drugs function by blocking dopamine D2 
receptors; also, chronic use of psychomotor stimulants can induce psychotic symptoms and this 
supports the hyperdopaminergic basis for schizophrenia.
75
 Strong evidence supporting the 
increased dopaminergic activity in schizophrenia has come from imaging studies showing that 
the binding of radiolabelled dopamine D2 receptor ligands to D2 receptors is displaced by 
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amphetamine-induced dopamine release, and this effect is increased in schizophrenia.
75
 One 
study showed that a low dose of amphetamine worsens psychosis in patients with schizophrenia, 
and the severity of this response was correlated to the estimated release of dopamine.
75
 
        The presence of amphetamine sensitization in humans has been obtained indirectly from 
observing behavioral and psychological changes in chronic amphetamine abusers.
75
 The 
limitation of this approach is that it is primarily a correlation and it is not possible to rule out that 
the observed behavioral changes preceded the start of amphetamine abuse.
75
 There are some 
studies which provide direct evidence for amphetamine sensitization in drug-naїve human 
subjects.
75
 In one study, subjects were exposed to a single dose of amphetamine at three different 
time points, with certain pre-selected behaviors being recorded during the first and third 
amphetamine exposure.
75
 After full amphetamine treatment, subjects showed an increased rate of 
eye-blink responses and increased motor activity following the third amphetamine exposure, as 
compared to their response following the first or second exposures.
75
 Different studies conducted 
by another group provide additional evidence for amphetamine-induced behavioral changes and, 
further, showed that amphetamine exposure was associated with a decrease in D2 receptor 
radioligand binding ([
11
C]raclopride) in the ventral striatum following re-exposure to 
amphetamine, which indicates enhanced mesolimbic dopamine activity.
75 
 
B) Dopamine Transporter (DAT): 
        Dopamine (DA) is involved in the control of numerous functions including locomotor 
activity, reward mechanisms, cognition and neuroendocrine functions.
76
 In addition, the 
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importance of the dopamine system in the CNS has been established based on the finding that 
dysfunction of this system is related to a broad spectrum of neuropsychiatric disorders, such as 
Parkinson’s disease (PD), schizophrenia, Tourette’s syndrome, attention-deficit hyperactivity 
disorder, and drug addiction.
76
 Even though, there are many important physiological and 
pathophysiological functions, dopamine is synthesized and released only from a relatively 
discrete number of neurons.
77
 These dopaminergic neurons are primarily located in the ventral 
tegmental area and the substantia nigra from where they extend to areas in the striatum, the 
limbic system, and the cortex;
77
 consequently, it is important to study regulatory mechanisms 
relevant to the functioning of DA systems to understand the etiology of various disorders 
associated with it and to develop effective therapeutics.
78
 
        The DAT mediates reuptake of dopamine from the synaptic cleft into the pre-synaptic nerve 
terminus and thereby plays a critical role in terminating dopaminergic signaling and in 
maintaining a releasable pool of dopamine.
76
 The DAT, just like transporters for serotonin 
(SERT), norepinephrine (NET), GABA, glycine, creatine, taurine, and proline, is a member of 
Na
+
/Cl
-
-dependent transporter family. The DAT contains 12 transmembrane domains having 
both amino- and carboxy-termini projected into the cytoplasm.
79
 DATs transport DA through 
sequential binding and cotransport of two Na
+
 ions and one Cl
-
 ion in association with one 
molecule of DA.
79
 Expression of DAT is exclusive to the dopaminergic nerve bodies and 
terminals and can serve as a selective marker of these dopaminergic neurons.
79
 In the brain, DAT 
is expressed highest in the striatum and nucleus accumbens followed by the olfactory tubercle, 
hypothalamic nuclei, and pre-frontal cortex.
79
 DAT expresses in peripheral areas including the 
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retina, gastrointestinal tract, lung, kidney, pancreas, and lymphocytes.
79
 DAT is mostly localized 
perisynaptically rather than in the synaptic compartment based on ultrastructural analysis which 
supports the previous estimations that reuptake of dopamine occurs at a distance from release 
site.
79
 
        DAT-KO mice are hyperactive, dwarf, and display cognitive and sensorimotor gating 
deficits, and sleep dysregulation.
80
 Normal social interaction has been seen in the mutant mice, 
but DAT-lacking females show an impaired capability to care for their offspring, most probably 
due to anterior pituitary hypoplasia-related hormonal dysregulation.
80
 DAT is the major target of 
the widely abused psychostimulant drugs cocaine and amphetamine.
76
 But, these drugs act 
through different mechanisms.
76
 Cocaine binds to the DAT substrate binding site and blocks 
transporter activity as a competitive inhibitor, while amphetamine is a transporter substrate able 
to promote DAT-mediated dopamine release.
76
 
        In DAT-KO mice, due to disruption of clearance of the released DA, there is about a 300-
fold increase in the lifetime of DA in the extracellular space, as shown by cyclic voltametry 
measurements, and in vivo microdialysis at least five-fold elevation in the basal extracellular DA 
levels.
79
 In addition, a profound depletion of intraneuronal dopamine stores (20-fold) and an 
attenuated level of evoked dopamine release (4-fold) was found in DAT-KO mice. Due to lack of 
dopamine-uptake-mediated recycling, the amount of dopamine in the striatum depends on the 
rate of its ongoing synthesis in these mice.
79
 Inhibition of tyrosine hydroxylase (TH), the rate-
limiting enzyme in DA synthesis, essentially eliminates dopamine in the striatum of mutant 
mice.
79
 Therefore, in DAT-KO mice, the DA levels are represented basically by a newly 
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synthesized pool.
79
 Thus, in the normal situation, major DA storage pools in the presynaptic 
striatal terminals must be regulated by DAT-mediated DA recycling based on these 
observations.
79
 
        Dopamine receptors undergo regulation due to the persistent increased dopaminergic tone.
81
 
Due to a marked desensitization of the major autoreceptor functions, there is loss of functional 
activity of autoreceptors observed as response to regulation of neuronal firing rate and DA 
release and synthesis.
81
 In DAT-KO mice, D1 DA receptors are down-regulated by 
approximately 50% in the striatum, but paradoxically, the postsynaptic DA receptors belong to 
certain populations that appear to be supersensitive.
79
 
        In addition to DAT function in the regulation of efficacy of DA transmission, it plays a 
major role in neurotoxic reactions induced by large doses of amphetamine derivatives and 
dopaminergic neurotoxins.
79
 In experimental animals Parkinson’s disease (PD) can be modeled 
by toxic lesions of dopaminergic neurons using MPTP.
79
 MPTP-induced death of dopaminergic 
neurons is due to its reactive metabolite 1-methyl-4-phenylpyridium (MPP
+
) which is known to 
transport into dopaminergic terminals through the DAT.
82
 As per prediction, a lack of MPTP 
neurotoxicity was found in DAT-KO mice.
79
 In DAT-KO mice, a significant reduction of 
dopaminergic neurotoxicity and lethality was observed even after administration of a neurotoxic 
regimen of methamphetamine-related compounds.
79
 Thus, it is clear that the DAT is critical for 
the degeneration of presynaptic DA neurons primarily by allowing entry of toxic compounds into 
the dopaminergic neurons.
79 
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C. Regulation of the Dopamine Transporter: 
        Numerous studies have been conducted to understand the cellular mechanisms responsible 
for regulating the availability and activity of the DAT in the presynaptic membrane.
76
 Several 
proteins have been identified, including kinases, receptors, and scaffolding protein, that modulate 
the catalytic activity of the DAT or its trafficking by their interaction with the DAT.
76
 
        DAT is exposed to dynamic regulation in the plasma membrane.
76
 This regulation may be 
important in the sense that it provides the strength to dopaminergic signaling which can be either 
attenuated or intensified.
76
 The regulatory effect of protein kinase C (PKC) activation has been 
studied.
76
 It has been shown in various studies involving several heterologous cell lines 
transfected with DAT that activation of PKC by phorbol esters, like phorbol 12-myristate 13-
acetate, down-regulate DAT capacity.
83-88
 The sustained DAT down-regulation due to PKC 
activation results most likely from DAT endocytosis.
76
 The PKC-induced inactivation of DAT is 
independent of DAT phosphorylation by PKC.
76
 In PKC-activated DAT down-regulation, 
involvement of another post-translational modification, ubiquitination, has been seen in recent 
studies.
76
 Ubiquitination regulating protein homeostasis is a widespread post-translational 
modification.
76
 In studies conducted by Miranda et al.,
89
 it was shown that DAT is ubiquitinated 
and this is augmented upon phorbol 12-myristate 13-acetate stimulation. The ubiquitination was 
dependent on the presence of three lysines at the intracellular N-terminus (lysine 19, lysine 27, 
and lysine 35) of DAT and mutation of these residues to arginine residues essentially diminished 
DAT down-regulation.
76
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        In the DAT C-terminus, a motif has also been shown to be essential for DAT 
internalization.
90
 The motif consist of a stretch of 10 residues of amino acids (587-596 in hDAT) 
which upon mutation to alanines caused impairment of both constitutive and PKC mediated 
DAT internalization.
90
 Additionally, it was reported that substitution of only 587-590 residues 
with alanine was sufficient to diminish PKC-associated DAT down-regulation and increase 
constitutive DAT internalization.
91
 This study suggested that the stretch of four residues is part 
of an endocytosis braking mechanism, which is relieved upon PKC stimulation.
91
 
        MAPK has been found to regulate DAT; for example, in transfected HEK293 cells and in 
striatal synaptosomes MAPK inhibitors were shown to decrease dopamine uptake.
92
 This might 
be due to alteration in DAT transport capacity and redistribution of DAT from the plasma 
membrane to the cytosol.
92
 Moreover, DAT regulation might be subject to regulation by 
phosphatases, as it has been reported that DAT exists in a complex with protein phosphatase 
2A.
93
 DAT substrates and inhibitors are also involved in regulation of DAT surface levels.
76
 
Both amphetamine and cocaine promote internalization of DAT whereas cocaine increases DAT 
surface levels.
76
 The mechanism behind this and responsible protein-protein interactions are still 
poorly understood.
76
 
        Lewy bodies, aggregation of α-synuclein in protein inclusions, are characteristic for the 
pathology of Parkinson’s disease (PD).76 In PD pathogenesis a role for synuclein is supported by 
the observation that point mutations in the α-synuclein gene as well as multiplications of the wild 
type gene have been identified in a rare familial form of PD.
76
 It has been reported that α-
synuclein binds directly to the C-terminal tail of DAT and was shown to involve the last 22 
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amino acids of DAT and the non-amyloid beta component domain of α-synuclein.94 An increase 
in dopamine-uptake was observed in Ltk-mouse fibroblasts in cells co-expressing α-synuclein 
and DAT compared to cells expressing α-synuclein and DAT alone and dopamine-induced 
cellular apoptosis was also observed.
94
 The coupling of α-synuclein to DAT was confirmed by 
Wersinger and Sidhu;
95
 however, they observed a reduction in dopamine uptake upon over-
expression of α-synuclein in the Ltk-cells. These controversial results might reflect differences in 
the level of α-synuclein over-expression, similar results were obtained in the regulation of NET 
by α-synuclein.96 So far no alteration in DAT function has been observed in α-synuclein knock-
out mice.
76
 
        Two studies have given evidence that the dopamine D2 receptor short variant (D2Rs), 
presynaptic autoinhibitory receptor expressed in dopaminergic neurons is likely to regulate DAT 
function.
97,98
 D2Rs directly interacts with DAT; this has been seen in co-immunoprecipitation 
and GST fusion protein pull-down experiments in striatal tissue extracts.
98
 The evidence suggests 
that the interaction depends on residues 1-33 in the DAT N-terminus and residues 311-344 in the 
D2Rs third intracellular loop.
98
 DAT with over-expressed D2Rs in a cell line increases dopamine 
uptake by 30-60%, mostly through an increased DAT surface expression and independent of the 
presence of D2R ligands.
98
 In addition, the dopamine D3 receptor, another D2-class receptor, was 
shown to up-regulate DAT surface expression in transfected HEK293 cells upon activation; 
however, the interaction of DAT and the D3 receptor was not investigated.
99
 
        The orphan receptor GPR37 has also been recently suggested to interact with DAT.
100
 DAT 
function was increased in GPR37 knock-out mice through an increased DAT expression, and 
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was suggested to involve an interaction between DAT and GPR37.
100
 In transfected HEK293 
cells, the putative physical interaction was only supported by co-immunoprecipitation 
experiments and immunofluorescence co-localization.
100
 Thus, additional studies have to be 
conducted to explore the significant of a putative DAT/GPR37 interaction.
76
 
        The scaffolding proteins are multiple protein interaction domains, serving as assembly 
modules and glue together the proper interaction partners.
76
 This includes proteins connecting 
membrane to their downstream signaling partners or anchoring them in the right cellular 
microdomains.
76
 Various studies have been done to investigate putative proteins and protein 
domains involved in DAT scaffolding.
76
 The most widespread protein domains known as PSD-
95/Discs-large/ZO-1 homology (PDZ) domains in cellular scaffolding processes have been 
investigated.
76
 The C-terminus of DAT has a canonical PDZ-binding sequence and in a yeast 
two-hybrid screen the C-kinase 1 (PICK 1) was discovered as a DAT interaction partner.
101
 Co-
immunoprecipitation experiments in brain tissue extracts suggested that this interaction promotes 
DAT surface expression and induces a clustering phenotype in transfected cells.
101
 However, this 
finding was challenged by Bjerggaard et al.,
102
 who showed that although PICK 1 binds the 
extreme DAT C-terminus, the interaction does not play a role in ER export and surface targeting 
of the transporter. C-Terminal residues of DAT are important for proper membrane targeting of 
DAT, however, mutations in DAT were identified, which was shown to disrupt PDZ domain 
interactions without affecting surface targeting, and mutations were recognized that disrupted 
surface targeting without affecting PICK 1 binding.
102
 Thus, the functional significance of the 
DAT-PICK 1 interactions still remained to identify.
76 
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D. Classes of Drugs acting through DAT:
 
        Psychostimulants are agents which enhance extracellular DA concentration. There are two 
classes of psychostimulants based on their mechanism by which they affect the DAT:
78
 1) uptake 
blockers and 2) releasers. 
        These classes of psychostimulants are based on their effects on acute neurotransmitter flux 
through the DAT.
78
 However, releasers may have some ability to act as uptake blockers and 
uptake blockers can have some ability of releasing neurotransmitter, but this general separation 
of drugs into two classes helps to distinguish the pharmacological profiles of the most commonly 
used psychostimulants.
78
 
 
1. Uptake blockers: 
        Based on their effect on DAT, cocaine and methylphenidate (MPD) are the best-
characterized uptake blockers.
78
 Cocaine and MPD share common binding on the DAT system
102
 
and their mechanism of action on the DA systems are similar.
78
 
        The primary mechanism of action of cocaine and MPD is to bind directly and inhibit the 
transport of DA through the DAT.
104
 There is an increase in extracellular DA levels due to 
blockade of DAT activity and is not related with selective longterm toxicity to the nigrostriatal 
DA pathway.
105
 It has been seen that there is an increase in DA uptake in synaptosomes prepared 
from treated rats, a preparation from which the drug has been presumably washed out, due to 
blockade of DAT by cocaine.
106
 This may be due to the increased recruitment of DATs to the 
plasma membrane.
78
 After cocaine administration in rodents and cell lines, respectively, this 
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acute increase in DA uptake and plasmalemmal surface expression was observed, likely due to 
maintain normal synaptic DA function.
78
 
        In humans, those who have acutely enhanced synaptic DA levels through the use of cocaine, 
enhanced DAT function is observed in synaptosomes from cryoprotected human brain.
107
 The 
development and expression of cocaine addiction is most likely based on the combination of an 
initial DAT blockade and a subsequent increase in DA uptake.
78
 The drug dependence, perhaps 
developed by an overabundance of extracellular DA due to DAT blockade which initiates a 
compensatory increase in DAT activity, leads to a deficit of extracellular DA.
78
 
 
2. Releasers: 
        Amphetamine-like psychostimulant drugs that are classified as “releasers” include 
amphetamine (1), methamphetamine (METH, 2), and 3,4-methylenedioxymethamphetamine 
(MDMA, 13).
108,109
 These releaser drugs increase DA release by disrupting vesicular pH 
gradients allowing vesicular DA to redistribute into the cytoplasm.
108,109
 As cytoplasmic DA 
levels rise, DA leaves the neuron through reverse transporter and/or channel-like activity of the 
DAT,
110, 111
 which causes a drastic increase in synaptic DA levels.
78
 
        In rats, injection of METH (2) in a single high-dose (10 mg/kg) rapidly (within an hour) and 
reversibly decreases the amount of DA taken up into synaptosomes developed from treated 
rodents.
112
 Rapid exposure to amphetamine reduces plasma membrane-associated DAT 
demonstrated by data from cell lines expressing the DAT, most likely representing a significant 
shift of the DAT protein to the cytosolic fraction.
113
 It is difficult to extrapolate the time course 
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of DA release via the DAT and a reduction of DAT on the cell surface in vivo, while, most 
probably, releasing drugs enhance initial DA release followed by a removal of DAT from the cell 
surface.
78
 
 
Table 3. Pharmacological profile of selected agents in dopamine, norepinephrine and 5-HT 
release assays.
114 
Drug Release 
NET 
EC50(nM) 
Release 
DAT 
EC50 (nM) 
Release 
SERT 
EC50 (nM) 
S(+)-Amphetamine          7.07  24.8 1765 
S(+)-Methamphetamine        12.3  24.5   736  
S(-)-Methamphetamine        28.5              416 4640  
S(+)-MDMA      136               142    74  
S(-)-MDMA      560            3700   340 
 
        With higher doses of releasers, the effects become more complicated and cause persistent 
deficits in striatal DA systems (such as 4x10 mg/kg/injection of METH at 2-hour intervals).
115
 
As compared to single injection of METH, multiple high-dose administration leads to a rapid 
(within an hour after final METH injection) decrease in DAT activity; however, this reduction in 
DAT is substantially greater and may be associated to persistent dopaminergic deficits.
115
 The 
mechanism behind this releaser-induced toxicity is not completely understood, but most likely 
increased DA, hyperthermia and oxygen radicals contribute to this phenomenon.
115
 
        In addition to changes in DAT activity induced by releasers, it has been demonstrated that 
higher doses of these drugs cause physical alterations in DAT, most likely a neurotoxic regimen 
of METH induces DAT complex formation.
116
 Whether these protein complexes at the site of 
  
32 
 
production are homomeric or heteromeric are not clear, however, when neurotoxic regimens of 
METH are administered.
78
 These complexes are seen to be associated with toxicity as their 
production is dependent on DA, hyperthermia, and reactive species,
117
 which are requisite factors 
for the METH-induced persistent DA deficits in the striatum. The functional influence of 
METH-induced DAT complex formation still needs to be determined.
78
 
 
E. Cathinone: 
 
1. Historical Background: 
        “Khat (Catha edulis, Celestraceae) is a flowering plant, indigenous to tropical East Africa 
and the Arabian Peninsula. The origins of the plant are often argued. Many believe its origins 
are Ethiopian, others state that khat originated in Yemen before spreading to Ethiopia and the 
nearly countries Arabia, Kenya, Somalia, Uganda, Tanzania, Malawi, Congo, Zambia, 
Zimbabwe and South Africa; it has also been found in Afghanistan and Turkestan. The ancient 
Ethiopians considered the plant a “divine food”, while the Egyptians used the plant for more 
than its stimulant effects. They used it in a metamorphic process to transcend into “apotheosis”, 
thus the human being was made “god-like”. The earliest documented description of khat dates 
back to the Kitab al-Saidana fi al-Tibb, an 11
th
 century work on pharmacy and material medica, 
written by Abu Rayhan al-Biruni, a Persian scientist.
”118 
        “The name Catha edulis was first given to the plant by Forsskal in 1775, and this name has 
since been used by most authors. (other locally used names are: qut, q’ut, kat, kath, gat, chat, 
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tschat, miraa, and murungu; the dried leaves of the plant are known as Abyssinian tea, Arabian 
tea or Bushman tea). Catha edulis is a shrub or decorative tree growing 1-25 m tall and is 
widely distributed in Africa. The leaves are elliptic to oblong, pendulous, leathery, bright green 
and shiny above, paler below with an evenly toothed margin. They are 5-10 cm long and 1-4 cm 
wide. Khat grows in habitals varying from evergreen submontane forest to deciduous at 800-
2000 m altitude and is now indigenous in Ethopia, Kenya, Uganda and Tanzania, and from East 
Congo (formerly Zaire) southward to South Africa. Very recently it has been introduced to 
Somalia.”118 
        Chewing leaves of the khat plant, in areas in which the plant is indigenous, is a habit due to 
its pleasurable stimulant effect.
119-121
 It has been estimated that about 5-10 million people chew 
the leaves every day.
119-121
 For example, in Yemen 60% of the males and 35% of the females 
chewed khat leaves for long periods of their lives.
119-121
 Khat leaf chewing induces stimulant 
effects and produces a certain degree of euphoric effect.
119-121
 It was reported by Alles et al.
122
 
that quantitative comparisons in man of the central stimulant aspects of khat plant material, its 
aqueous extracts, and its detannated extracts, gave results that corresponded to the amount of 
dextro-norpseudoephedrine isolated. These desirable effects are only produced by fresh leaves, 
so that until the present time the chewing habit has remained in those areas where the plant is 
indigenous.
119-121
 After harvesting, khat is sold as a bundle of twigs, stems and leaves, and is 
wrapped in banana leaves to preserve freshness.
118
 During the past few years because of rapid 
and relatively inexpensive transportation, the drug has been reported in Great Britain, Italy, The 
Netherlands, Canada, Australia, New Zealand, the USA, and Hungary.
118
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        Khat has been traditionally used as a socializing drug and this is still the case.
123
 In the 
countries where it grows, it is used as a recreational drug, also it may be used by farmers and 
agricultural and other laborers for decreasing physical fatigue and by drivers and students for 
increasing attention.
123
 At the age of 10, children often start chewing khat.
123
 At present, khat is 
so popular in Yemen that about 40% of the country’s water supply goes towards irrigation of 
khat plants.
123
 
        In the USA a kilo of khat is being sold for $300-500 and a bundle of leaves sold for $30-
50.
124
 It has been seen that there is an increase in use of khat in the upstate New York area.
124
 
The USA Drug Enforcement Administration (DEA) executed operation Somalia Express in July 
2006, an 18-month investigation that resulted in the coordinated takedown of a 44-member 
international trafficking organization that was responsible for smuggling 25 tons of khat from the 
Horn of Africa to the USA, which was worth more than $10 million according to DEA 
estimation.
124
 
        It is reviewed that in 1887, Flücklger and Gerock first attempted to isolate the active 
principle of the plant.
119
 It is reviewed that Wolfes identified norpseudoephedrine in khat leaves 
in 1930 and in 1941, Brücke stated that the amount of norpseudoephedrine in khat was 
insufficient to account for the symptoms produced.
118
 Due to this statement, the plant was 
reinvestigated and studies resulted in isolation of the keto-analog of norpseudoephedrine from 
khat leaves, and cathinone (β-keto-amphetamine; 23) was suggested as the name for this 
alkaloid.
125-129
 The khat plant contains the phenylalkylamine cathinone ((-)-cathinone) and the 
diastereoisomers cathine (1S,2S-(+)-norpseudoephedrine or (+)-norpseudoephedrine) and 
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norephedrine (1R,2S-(-)-norephedrine).
130
 These phenylalkylamines are structurally similar to 
amphetamine and noradrenaline.
130
 The khat plant contains the (-)-enantiomer, but not the (+)-
enantiomer of cathinone.
130
 
        Cathinone is chemically unstable, undergoes decomposition reactions after harvesting and 
during drying or extraction of the plant material.
118
 Cathinone generally decomposes to a dimer 
(3,6-dimethyl-2,5-diphenylpyrazine) and most likely to some small fragments.
131
 This is the 
reason why users prefer the fresh leaves as cathinone is the psychoactive component of khat.
118
 
The content of phenylalkylamines in khat leaves varies within wide limits.
118
 A 100 g sample 
khat of leaves contains, on average, 36-114 mg cathinone, 83-120 mg cathine and 8-47 mg 
norephedrine.
132-134 
 
2. Pharmacology: 
        (-)-Cathinone has a positive inotropic and chronotropic effect in isolated guinea pig atria.
135
 
In whole animal, (-)-cathinone and (+)-amphetamine were found equipotent in increasing the 
heart rate when injected i.v. at a dose of 1 mg/kg.
135
 It was reported that (-)-cathinone has a 
pressor effect in anaesthetized cats; when administered i.v. 1 mg/kg resulted in a transient rise in 
the blood pressure by 30 to 35 mmHg.
130
 
        As like (+)-amphetamine, (-)-cathinone produces hyperthermia in rabbits after its injection 
and reduces the body temperature of rats previously exposed to a cold temperature.
135
 (-)-
Cathinone produced long lasting analgesia in rats using the tail-flick test, and the duration of 
analgesic effect was dose related.
130 
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        It has been reported that s.c. administration of cathinone in rats increases the locomotor 
activity of the animals, and that (±)-cathinone had a potency approaching that of (+)-
amphetamine.
135
 Van der Schoot et al.
21
 found (±)-cathinone to produce half the maximal 
locomotor effect of (+)-amphetamine in mice, but specific doses were not provided. 
Quantitatively, in another study using mice, the locomotor activity of (-)-cathinone was one-
seventh of the potency of (+)-amphetamine.
136
 The dose-response curve of cathinone’s effect on 
locomotor activity was observed to be an inverted-U shape, which is typical of stimulants of the 
amphetamine type.
130 
Reserpinization only partially antagonized the locomotor response of mice, 
which is similar to that for (+)-amphetamine hypermobility.
137
 In order to find out whether the 
stimulation of locomotor activity involves activation of dopamine receptors as in the case of (+)-
amphetamine, the effect of dopamine receptor antagonists, like haloperidol, spiroperidol and 
pimozide were investigated.
137
 It was seen that dopamine receptor antagonists blocked the 
locomotor response to (-)-cathinone; this finding is in agreement with those for (+)-
amphetamine.
137 
        Pretreatment of the animals with the catecholamine synthesis blocker α-methylparatyrosine, 
completely blocked the induction of stereotyped behavior by (-)-cathinone.
135
 However, 
pretreatment of animals with the dopamine receptor antagonist haloperidol reduced biting and 
licking movements induced by cathinone.
138
  
        (-)-Cathinone has been reported to act as anorectic compound in behavioral experiments 
with monkeys.
131
 In rats, intracerebroventricular injection of (-)-cathinone inhibits food intake to 
a greater extent than amphetamine.
131
 In rats, it has been reported that i.p. injection of racemic 
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cathinone resulted in reduced food intake, and that chronic administration led to a decrease in 
body weight.
139
 In this study, (+)-amphetamine was seen more potent than cathinone.
139 
        The similarity of cathinone to amphetamine was shown by Rosecrans et al.
37
 who reported 
that racemic cathinone could be substituted for (+)-amphetamine in rats trained to distinguish 
between a placebo and (+)-amphetamine. When administered cathinone, the animals responded 
the same as if they had been given (+)-amphetamine, and this response was dose related.
37
 It has 
been seen that cathinone and (+)-amphetamine produced the same response pattern and were 
equipotent in drug-discrimination studies in rats trained to discriminate (+)-amphetamine from 
vehicle.
29
 Cathinone has a more rapid onset of action compared to amphetamine based on drug 
discrimination experiments.
140
 (-)-Cathinone (i.e., S(-)23) is several times more potent compared 
to (+)-cathinone (i.e., R(+)23) in producing central stimulant and drug discriminative stimulus 
effects, while (+)-amphetamine (i.e., S(+)1) is more potent than (-)-amphetamine (i.e., R(-)1).
141 
However, (-)-cathinone (S(-)23) and (+)-amphetamine (S(+)1) have the same absolute 
stereochemistry (i.e., S), so that S(-)-cathinone (S(-)23) structurally resembles S(+)-amphetamine 
more than R(-)-amphetamine (R(-)1).
141
 Cathinone’s discriminative stimulus effects were not 
blocked by the serotonin antagonist BC105/B.
126
 It was reported by Glennon et al.
142
 that rats 
trained in a two-lever drug-discrimination procedure were less likely to distinguish between (-)-
cathinone (S(-)23) and quipazine, a serotonin receptor agonist, than between (+)-amphetamine 
(S(+)1) and quipazine. However, it was found that chronic treatment of rats with racemic 
cathinone reduces the level of dopamine in several brain areas but does not affect the level of 
serotonin.
125
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         In monkeys trained to press a lever for cocaine injection, the animals continue to respond at 
high rates when the training drug was replaced with (-)-cathinone.
143
 In this study, the 
reinforcing effect of (-)-cathinone was reported to be greater than (+)-amphetamine.
143
 Cathinone 
may produce rates of responding higher than amphetamine based on self-administration 
experiments with monkeys.
129
 
        It has been reported that cathinone modified brain catecholamine turnover, but to a lesser 
extent than (+)-amphetamine.
37
 In mice, pretreated with (-)-cathinone, the turnover of dopamine 
increased by 32%, but that of norepinephrine was practically unaffected.
144
 In rats, repeated 
administration of racemic cathinone produced a long-lasting depletion of dopamine in several 
brain regions, with no effect on the level of norepinephrine.
144
 It has been found in an assay 
system involving beef monoamine oxidase and benzylamine as a substrate, that (-)-cathinone 
was considered more potent in inhibition of monoamine oxidase than racemic amphetamine.
145 
        There are two possible mechanism of cathinone action: that its effects may be produced by 
a blocking of the reuptake of, primarily, physiologically released dopamine, and another 
possibility would be that cathinone acts by inducing the release of, primarily, presynaptic storage 
dopamine, a mechanism considered of importance for amphetamine on dopaminergic 
transmission.
146
 Therefore, the efflux of radioactivity from rabbit caudate nucleus prelabeled 
with 
3
H-dopamine induced by (-)-cathinone was studied.
147
 It was observed that superfusion of 
the tissue with 4 μM (-)-cathinone resulted in a rapid and reversible increase of efflux of 
radioactivity which was comparable to that produced by the same concentration of (+)-
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amphetamine.
147
 A releasing effect for racemic cathinone also was found in 
3
H-dopamine-
preloaded synaptosomes obtained from rat neostriatum.
144
   
        In conclusion, based on various studies, it is known that cathinone is in a real sense a 
natural amphetamine while being the major psychostimulant constituent of khat.
129
 See Figure. 2 
for a structural comparison of these and related agents. It might be noted that there are some 
discrepancies in the studies that have used cathinone and these can probably be attributed to 
species differences, or the use by various investigators of either (±)- or (-)-cathinone. For 
example, whereas (-)-cathinone is a locomotor stimulant, (+)-cathinone decreases the locomotor 
action of mice up to a dose of 100 μmoles/kg; (±)-cathinone produces intermediate results.136 
Nevertheless, cathinone has a pharmacological profile same as that of amphetamine: cathinone 
shows the same actions of amphetamine on the CNS as well as its sympathomimetic effects.
129
 
The major difference among the two drugs is the shorter duration of the action of cathinone; its 
reduced stability promotes a more rapid inactivation.
129
  
                            
 
Figure 2. Stereochemistry of amphetamine (1), methamphetamine (2), cathinone (23) and 
methcathinone (24) isomers. 
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3. Cathinone Analogs: 
        Cathinone/methcathinone analogs are structurally-related to amphetamine/ 
methamphetamine derivatives but bear an additional β-keto group. The structural relationships 
among representative examples of these agents are shown in Figure 3. 
 
Figure 3. Structural relationship between amphetamine (AMPH), methamphetamine (METH) 
and their β-keto or cathinone (CATH) or methcathinone (MCAT) counterparts. 
 
         Glennon et al.
136
 examined the effects of various substituent groups on racemic cathinone 
on locomotor activity. They found that 2-methoxy, 4-methoxy (i.e., 32), 2,4-dimethoxy and 4-
fluoro (i.e., 29) derivatives of racemic cathinone failed to produce locomotor stimulant 
activity.
136
 They also found that the α-desmethyl analog of cathinone had no significant effect on 
locomotor activity.
136
 Furthermore, it was reported that stimulus generalization occurs between 
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(+)-amphetamine and cathinone regardless which drug is used as the training drug.
148
 2-
Aminotetralone, a conformationally restricted cathinone (ringcathinone), produced saline-
appropriate responding in rats trained to discriminate (+)-amphetamine from saline.
148
 In the 
same studies, N,N-dimethylaminopropiophenone and α-desmethylcathinone failed to produce 
(+)-amphetamine-like effects.
148
 
                        
        Cathinone is a naturally occurring amphetamine-like substance and both share similar 
pharmacological effects.
141
 If parallel structural modification results in parallel changes in action 
and potency, N-monomethylation of amphetamine should enhance potency. That is, N-
monomethylamphetamine (methamphetamine) is twice as potent as amphetamine as central 
stimulant. Hence, N-monomethylation of cathinone, not surprisingly, should be more potent than 
cathinone both as locomotor stimulant in mice and in tests of stimulus generalization in rats 
trained to discriminate (+)-amphetamine from saline vehicle. This was found to be the case.
149
 
Glennon et al.
149
 termed this substance methcathinone (24).
 
        N-Methylcathinone was first synthesized by the Germans
150,151,152
 and the French
153
 as well 
as Adams
154
 and co-workers in the late 1920’s as an intermediate in the synthesis of ephedrine  
and was first mentioned by Chen et al.
155
 in 1926. The two isomers of N-methylcathinone were 
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first reported in 1936
156
 and the (-)-isomer was thereafter patented as an analeptic.
157,158
 It was 
found that methcathinone is more potent than cathinone both as a locomotor stimulant and in test 
of stimulus generalization using rats trained to discriminate (+)-amphetamine from saline.
141 
In a 
locomotor stimulant test in mice, S(-)-methcathinone (i.e., S(-)24) was five times more potent 
than its optical isomer.
149
 S(-)-Methcathinone (S(-)24) was nearly three times more potent than 
R(+)-methcathinone (i.e., R(+)24) with racemic methcathinone potency falling between the 
potencies of the two isomers in drug discrimination studies using cocaine-trained rats, and S(-)-
methcathinone (S(-)24) was more potent than R(+)-methcathinone (R(+)24) in same test using 
S(+)-amphetamine-trained animals.
141
 Thus, all three results are in agreement that S(-)-cathinone 
(S(-)23) is more potent than R(+)-cathinone (R(+)23) where the S-isomer of amphetamine is 
more potent than R-isomer of amphetamine. 
        In 1997, Glennon
159
 and co-workers wished to determine whether structural modification of 
cathinone paralleled the effects observed upon structural modification of amphetamine. They 
tested several N-alkylated and methylenedioxy-substituted analogs of cathinone and compared 
them with amphetamine analogs. Similar to amphetamine, N-monomethylation of cathinone was 
found to retain potency, while any further increase in alkyl chain length was found to decrease 
potency.
159
 It was surprising for them that (+)-N,N-dimethylamphetamine resulted in a 7-fold 
decrease in potency over (+)-methamphetamine (i.e., S(+)2) in producing (+)-amphetamine 
appropriate responding in rats trained to discriminate (+)-amphetamine from saline, while (±)-
N,N-dimethylcathinone (36; see Table 5) was found only slightly (1.6 fold) less potent than 
racemic methcathinone.
159
 Based on the knowledge that incorporation of a 3,4-methylenedioxy 
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group can change amphetamine from a CNS stimulant to a combination of CNS stimulant, 
hallucinogenic (DOM-like) and empathogenic (MDMA-like) agent (i.e. MDA, 12), Glennon and 
colleagues studied the 3,4-methylenedioxy derivatives of cathinone and methcathinone.
159
 It was 
found that the 3,4-methylenedioxy analog of cathinone (i.e. MDC, 34), failed to completely 
substitute for (+)-amphetamine or DOM, so introduction of a carbonyl group resulted in an agent 
which no longer acts like its parent compound (MDA, 12).
159
 The 3,4-methylenedioxy analog of 
methamphetamine, MDMA (13) shows amphetamine-like effect but lacks DOM-like 
character.
159
 N-Monomethylation of MDC (34) results in an agent (i.e. MDMC, 35) which 
behaves similar to MDMA (13).
159
 It was interesting that, both MDC (27) and MDMC (35) show 
MDMA-like properties in MDMA-trained rats.
159
 It was found that with MDMA (13), 
introduction of carbonyl group resulted in a compound (i.e. MDMC, 35) which is less potent 
(about two-fold). 
        MDMC (35) was first patented by Jacob III et al.
160
 and they called this substance 
methylone. Cozzi et al.
161
 have compared methcathinone (24) and methylone (MDMC, 35) to 
methamphetamine (2) and MDMA (13) for their abilities to inhibit 
3
H-serotonin, 
3
H-dopamine, 
and 
3
H-norepinephrine uptake via the plasma membrane uptake transporters and they also tested 
inhibition of 
3
H-serotonin uptake by the vesicular monoamine transporter, VMAT-2 (Table 4). 
They found that methcathinone (24) and methylone (35) were as potent as the respective 
methamphetamine (2) and MDMA (13) at inhibiting monoamine accumulation, and all of the test 
drugs were more potent at the dopamine transporter than at the norepinephrine transporter.
161
 At 
the serotonin uptake carrier, methcathinone (24) and methylone (28) were one-third as potent as 
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methamphetamine (2) and MDMA (13), respectively.
161
 They found that methcathinone (24) and 
methylone (35) are highly selective for the plasma membrane catecholamine transporters and 
show decreased potency at VMAT-2 compared to methamphetamine (2) and MDMA (13), 
respectively.
161
   
      Table 4. IC50
 
values (μM) for drug inhibition of monoamine uptake.161 
Drug [
3
H] 5-HT [
3
H] DA [
3
H] NE VMAT2 
([
3
H] 5-HT) 
(±)-Methcathinone (24) 34.6 0.356 0.511 112.1 
(±)-Methamphetamine (2) 11.6 0.467 0.647   10.9 
(±)-Methylone (35)    5.75 0.819 1.220 165.6 
(±)-MDMA (13)   2.14 0.478 1.380  12.7 
 
        Methylone (35) abuse was first reported in 2004 as a liquid solution sold as a vanilla-
scented odorizer.
162
 Recently, it has been found that methylone is sold in plastic tubes containing 
5 mL of liquid called Explosion via the internet and in head shops.
163
 There is no significant 
clinical literature on the effects of methylone (35).
164 
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        Mephedrone (4-methylmethcathinone; 27) is a cathinone derivative, which elicits a 
stimulant effect like amphetamine (1), methamphetamine (2), cocaine and MDMA (13).
165
 
Recently, it has drawn media attention due to its link to a number of fatalities.
166
 Sachez 
described the first synthesis of mephedrone (27) in 1929.
167
 Due to the cathinone (23) ban, 
chemist started altering the structure of cathinone (23) to produce related unscheduled agents.
166
 
In May 2003, the first online report on mephedrone (27) appeared, however, the online 
availability and related popularity of mephedrone (27) started in 2007.
166
 The national Addiction 
Centre in London conducted research involving 2,295 readers of the dance magazine ‘Mixmag’ 
and reported that 41.7% of surveyed people had tried mephedrone (27) and 33.2% had used it 
during the previous month, showing its popularity among ‘clubbers’ and making it the sixth most 
popular drug, after tobacco, alcohol, cannabis, ecstacy and cocaine.
168
 In the UK, the Advisory 
Council on the Misuse of Drugs recommended inclusion of mephedrone (27) in the Misuse of 
Drugs Act 1971 under class B and as a result, it was made a controlled drug (class B) on the 16
th
 
of April 2010.
169
 
        Mephedrone (27) is the N-methyl cathinone analog of pTAP (16). It has been reported that 
pTAP produces partial stimulus generalization in rats trained to discriminate (+)-amphetamine 
from saline.
33
 Table 1 shows the potency of pTAP (16) as a releaser of monoamine 
neurotransmitters.
34
 pTAP (16) was found to produce positive reinforcing effects in monkeys.
34
 
In 2010, pTAP (16) was detected in seized amphetamine mixture containing amphetamine, 
caffeine, di-(phenylisopropyl)amine (DPIA) and some by products.
170
 There is not much known 
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about its N-methyl analogs 4-methylmethamphetamine (25) and 4-methylcathinone (26) which 
are, respectively, methamphetamine and cathinone counterpart of mephedrone (27). 
Since 2006, an additional 10 cathinones have been reported in the European Union (shown in 
Table 5).
169
 
Table 5. List of cathinones reported in Europen Union.
169
         
 
 *bk = beta keto.  
 
Name Common Name R
1
 R
2
 R
3
 R
4 
N,N-dimethylcathinone (36)  Me Me Me H 
Ethcathinone (37)  Me Et H H 
4-Methylmethcathinone (27) Mephedrone Me Me H 4-Me 
bk*-PMMA (33) Methedrone Me Me H 4-OMe 
4-Fluoromethcathionone (30) Flephedrone Me Me H 4-F 
3-Fluoromethcathionone (38)  Me Me H 3-F 
bk*-MDMA (35) Methylone; MDMC Me Me H 3,4-methylenedioxy 
bk*-MDEA (39) Ethylone Me Et H 3,4-methylenedioxy 
bk*-MBDB (40) Butylone Et Me H 3,4-methylenedioxy 
MDPV (41) Methylenedioxypyrovalerone n-Pr pyrrolidinyl 3,4-methylenedioxy 
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       Online purchase of mephedrone (27) is claimed to be ‘plant feeders’, ‘bath salts’, and  ‘not 
for human consumption’ and prosecution as such may be difficult. Mephedrone (27) is most 
commonly administered by insufflation (snorting) and oral ingestion.
171
 Also, because 
mephedrone (27) is soluble in water, it is used by rectal administration (dissolved in an enema or 
within gelatin capsules), or injected intravenously.
171
 Mephedrone (27) produces its effects 
within a few minutes after being snorted, with the peak effects reached in <30 mins leading to a 
rapid comedown.
171
 Snorted doses of mephedrone (27) range between 25 and 75 mg, with a 
threshold dose being 5-15 mg; 90 mg is considered a high dosage.
171
 Most commonly, oral 
dosages are, on average, higher than snorted doses, usually in a range between 150 and 250 mg, 
and the onset of action may be of 45 min to 2h.
171
 
        Self reported subjective effects of mephedrone (27) have been described, and include 
intense stimulation, alertness, euphoria, empathy/feeling of closeness, sociability, talkativeness, 
intensification of sensory experiences, moderate sexual arousal and perceptual distortions (only 
with higher doses).
168,172
 There are many unwanted effects associated with mephedrone (27) that 
have been reported: adverse effects related to the gastrointestinal system, central nervous system 
– neurological and psychiatric, cardiovascular system and renal/urinary excretory system.166 
These adverse effects are very similar to those already reported for amphetamine (1), 
methamphetamine (2) and MDMA (13), and support a sympathomimetic action by mephedrone 
(27).
166
 
        The first death related to mephedrone (27) appeared in Sweden in December 2008; only 
mephedrone (27) was identified by the toxicological screenings.
173
 The first mephedrone-related 
  
48 
 
death in the USA involved the combined use of mephedrone (27) and heroin.
174
 Based on the 
data obtained from the National Programme on Substance Abuse Deaths report, there have been 
45 suspected deaths in England associated with mephedrone (27), 12 in Scotland, 1 in Wales, 1 
in Northen Ireland and 1 in Guernsey, by the beginning of October 2010.
166
 Out of these 60 
cases, 48 provided positive results for the existence of mephedrone (27), while other cases need 
to be further investigated.
166
 
        Mephedrone (27), due to its popularity as a legal high, is now a substance controlled by 
legislation in the United Kingdom, Germany, Norway, Sweden, The Netherlands, Finland, 
Romania, Republic of Ireland, Denmark, Canada and Israel,
175
 as well as in US. Prevalence of 
cathinone (23) derivatives has given rise to both legal and analytical challenges in the 
identification of these substances.
175
 Thus, it is required to develop robust analytical profiling 
and validated methods of testing.
175
 Therefore, recently, many publications have reported the 
synthesis of mephedrone (27)
 
and methods for its identification.
175-178
 
        It has been found that bath salts contains methylenedioxypyrovalerone (i.e., MDPV; 41) in 
addition to mephedrone (27).
179
 Recently, The New York Times published an article showing the 
growing popularity of bath salts in the USA and discussed its danger among people using it.
180
 
Regarding bath salts, Karen E. Simone, director of the Northern New England Poison Center, 
says, “If you gave me a list of drugs that I wouldn’t want to touch, this would be at the top.”180 
Bath salts have been banned in 28 US states,
180
 inclunding Virginia. Westphal et al.
181
 identified 
a compound which was seized as a powder in Germany in 2007 as MDPV (41), a pyrovalerone 
carrying a methylenedioxy moiety. It has been reported that besides in Germany, MDPV (41) has 
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appeared in many countries in Europe and Asia.
182
 In June 2007 a customs officer in Germany 
seized MDPV (41) as a nearly pure substance while investigating a person who was the 
addressee of a drug mail shipment from China.
181
 In mice, MDPV (41) was found to have a 
milder effect on the increase of dopamine levels than methamphetamine (2) and MDMA (13), 
and showed no significant influence on serotonin levels.
183
  It has been seen that in locomotor 
activity MDPV (41) has a shorter duration of action compared to MDMA (13) and 
methamphetamine (2).
183
 MDPV (41) has gained popularity for claimed sex-enhancing 
properties.
184
 However, in the study of Ojanpera et al.
185
 the reputation of MDPV (41) as a sex 
drug was found less important; rather, a clear stimulation effect induced by MDPV (41) was seen 
in some patients. It was assumed that MDPV (41) is taken orally.
182
 Ojanpera et al.
185
 reported a 
GCMS method for the detection of MDPV (41) in urine together with the stimulants 
amphetamine, methamphetamine (2), and MDMA (13). In Japan, Uchiyama et al.
186
 found seven 
designer drugs in fifteen confiscated products, including: MDPV (41), bk-MBDB (40), bk-
MDEA (39), N-hydroxy-1-(3,4-methylenedioxyphenyl)-2-aminopropane (N-OH MDMA), N-
methyl-1-(4-fluorophenyl)propan-2-amine (N-Me-4-FMP; 30), and 5-methoxy-N-ethyl-N-
isopropyltryptamine (5-Meo-EIPT). In the United Kingdom, MDPV (41) was banned in 2010 by 
way of a generic definition.
187
 It has been reported that mephedrone (27), methylone (35) and 
MDPV (41) seizures collectively represented over 97% of the synthetic cathinone seizures.
188
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        Archer
189
 has reported that internet-based companies are known to sell 4-
fluoromethcathinone (flephedrone; 30), the N-methyl analog of 4-fluorocathinone (29), and he 
reported a method for the synthesis and identification of various fluoromethcathinones (includes: 
2-fluoromethcathinone (42), 3-fluoromethcathinone (38), 4-fluoromethcathinone (30)). There 
have been no animal studies reported using flephedrone (30). 
        Flephedrone (30) is the N-methyl cathinone analog of p-fluoroamphetamine (7). Table 1 
shows the invitro potency of p-fluoroamphetamine (7) as a releaser of monoamine 
neurotransmitters.
34
 p-Fluoroamphetamine (7) produced stimulus generalization in rats trained to 
discriminate (+)-amphetamine from saline.
25
 There is little known about p-
fluoromethamphetamine (28) and p-fluorocathinone (29) which are, respectively, 
methamphetamine and cathinone counterparts of flephedrone (30) but (±)-4-fluorocathinone (29) 
failed to produce hypermotor activity in mice.
136
 In 2003, a series of clandestinely prepared 
phenylalkylamines was seized in the federal state of Sachsen-Anhalt (Germany), which 
contained 4-fluoroamphetamine (7) as well as 4-fluoromethamphetamine (28).
190
 It has been 
reported that since 2008, larger quantities of drug preparations containing 4-fluoroamphetamine 
have been seized in several German federal states and in Switzerland.
191
 
        Methedrone (33), the N-methyl analog of 4-methoxycathinone (32), was reported as an 
abused substance for the first time in October 2009 and two deaths were partly attributed to 
methedrone (33) in Sweden.
192,193
 Wilkstrom et al.
194
 reported two deaths related to methedrone 
(33) due to its toxic properties and they found that blood concentrations in the two cases are 
close to those seen in subjects who abused the drug, suggesting that a rather narrow “therapeutic” 
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window exists for methedrone (33). This emphasizes the risks associated in taking this kind of 
drug for recreational purposes.
194
 Methedrone (33) is controled in Sweden and Romania.
164
 
There are no aminal or pharmacological studies on methedrone (33). 
        Camilleri et al.
176
 reported the results of chemical analysis of four capsules delivered to the 
Royal Adelaide Hospital (Australia), which originated from an Israel-based internet company, 
“Neorganics”. They found that capsule 1, which was marketed as “Spirit”, contained 4-
methylmethcathinone (mephedrone; 27); capsule 2, which was marketed as “Sub Coca 2”, 
contained α-phthalimidopropiophenone and 2-fluoromethcathinone (42); capsule 3 and capsule 
4, which were marketed as “Neo dove” and “Sub Coca”, respectively, both contained caffeine, 4-
methylmethcathinone (mephedrone, 27), N-ethylcathinone (37) and α-
phthalimidopropiophenone.
176
 Jankovics et al.
195 developed a “screening method” to provide a 
preferably simple and fast analytical procedure for the detection of methcathinone-derived 
designer drugs, including: mephedrone (27), methedrone (33), flephedrone (30), MDPV (37), 
methylone (MDMC; 35), butylone (i.e., bk-MBDB; 40) and 4-methylethcathinone (4-MEC).  
        Methedrone (33) is the N-methyl cathinone analog of 4-methoxyamphetamine (PMA, 11). 
In two separate studies, it has been observed that PMA (11) results in amphetamine stimulus 
generalization, but is less potent than amphetamine.
28,29
 Table 1 shows the invitro monoamine 
transporter release potency of PMA (11). PMMA (p-methoxymethamphetamine, 31), a 
methamphetamine counterpart of methedrone, failed to produce stimulus generalization in rats 
trained to discriminate (+)-amphetamine from saline.
30
 However, PMMA (31) produced 
complete stimulus generalization in rats trained to discriminate MDMA (13) from saline and was 
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three times more potent than MDMA (13).
196
 PMA (11) produced partial stimulus generalization 
in rats trained to discriminate PMMA (31) from saline.
197
 Shulgin has called PMMA (31) 
“DOONE”.198 PMA (11) has been found a potent hallucinogen.199 (+)-PMA and (-)-PMA failed 
to produce stimulus generalization in rats trained to discriminate (+)-amphetamine from saline, 
however (-)-PMA, but not (+)-PMA, substituted for PMMA (31) in PMMA (31) trained rats.
200
 
PMA (11) is classified as a Schedule I controlled substance.
201
 (+)-PMMA completely, while (-)-
PMMA partially, substituted for (±)-PMMA (31) in rats trained to discriminate (±)-PMMA from 
saline.
202
 Table 6 shows the potency of (+)-PMMA and (-)-PMMA as releasers of 
neurotrasmitters.
203
 It has been reported that PMA (11) produces little locomotor stimulation in 
mice at doses below 30 mg/kg and that PMMA (31) looks even less potent than PMA (11) at 
doses of up to 30 mg/kg.
30
 PMA (11), compared to (+)-amphetamine, is more effective in 
increasing the release and blocking the uptake of 
3
H-serotonin, while less effective in increasing 
the release and blocking the uptake of 
3
H-norepinephrine and 
3
H-dopamine.
204
 PMA (11) has 
been used illicitly in Australia since 1994 and later became popular at rave parties in the US.
36
 In 
2000, three fatal cases were reported involving PMA (11) and PMMA (31) abuse in Denmark.
205
 
4-Methoxycathinone (32), which is the cathinone counterpart of methedrone (33), failed to 
produce stimulus generalization in rats trained to discriminate cathinone from saline.
206
 It has 
been also reported that 4-methoxycathinone (32) failed to produce locomotor activity in mice.
136
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Table 6. In vitro potency as releasers of neurotransmitters.
203
 
Drug Release 
NET 
EC50 nM 
Release 
DAT 
EC50 nM 
Release 
SERT 
EC50 nM 
S(+)PMMA 147 1000 41 
R(-)PMMA   1600            > 14000  134 
 
        In conclusion, β-keto amphetamines, including: mephedrone (27), methedrone (33), 
flephedrone (30), MDPV (41), methylone (MDMC; 35) and many others, have recently become 
popular on the illicit drug market and, as discussed above, there are many reports regarding their 
abuse. Furthermore, although cathinone (23) and methcathinone (24) are controlled substances, 
their analogs are not. These drugs are a growing threat for society they financially, socially, as 
well as producing detrimental effects on health among their users. There is essentially nothing 
known about their pharmacology (except cathinone (23) and methcathinone (24)). Based on the 
structural similarity of these drugs to cathinone (23) and methcathinone (24), one might assume 
that their pharmacology and mechanism of action could be similar to cathinone (23) and 
methcathinone (24), but little is known based on current scientific data. One of the difficulties in 
studying these drugs is to obtain them in pure form. Bath salts (containing primarily methedrone 
(27) and MDPV (41)), as mentioned above, is recently gaining more and more in popularity on 
the illicit market. Certainly, based on increasing interest of these cathinone derivatives among 
abusers, there is a need for more research to determine how these drugs are producing their effect 
and also a need for validated techniques to screen potential candidates related to the cathinones 
which might become a future threat. 
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II. Specific Aims 
 
        The overall goal of the present project is to synthesize and initiate an examination of the 
mechanism(s) of action of a new class of abused substances known as “cathinones”, “synthetic 
cathinones”, or “β-keto amphetamines” and, more specifically, the constituents of “bath salts” 
and several structurally related agents. These substances represent a relatively new and fast-
growing class of designer drugs (Table 5). Although the first members of this class, cathinone 
(23) and methcathinone (24), were identified more than 30 years ago (see Introduction), it is only 
within the last few years that they have been acknowledged as representing the first members of 
an entire class of agents. These agents are, structurally, β-keto analogs of amphetamine and 
might be referred to as “amphetamones”. That is, the amphetamone counterpart of amphetamine 
(1) is cathinone (23), whereas that of methamphetamine is methcathinone (24). Although 
cathinone and methcathinone are Schedule 1 substances,
207
 analogs of these agents are 
essentially unregulated. It might be noted that certain states have controlled various specific β-
keto amphetamines, but they have not been regulated at the federal level. (“Bath salts”, itself, 
was placed in US Schedule 1
208
 only after the synthetic and pharmacological studies described 
below were completed.) 
        “Bath salts” is a combination of two cathinone or ‘synthetic cathinone’ analogs: 
mephedrone (27) and MDPV (41). Mephedrone is the amphetamone analog of N-methyl pTAP 
(i.e., 25). MDPV (41) is a co-constituent of “bath salts”; one explanation for its presence in the 
mixture is that it is a contaminant (i.e., a synthetic precursor of mephedrone). 
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However, it is difficult (if not impossible) to understand how mephedrone could be prepared 
from MDPV, or how MDPV could be a by-product of mephedrone synthesis. Another possibility 
is that MDPV is simply a “filler”. But, why go to the trouble of preparing this compound when 
much simpler “fillers” (e.g. lactose) could be used. A third possibility is that MDPV is 
behaviorally active. Yet, being a tertiary amine with a homologated α-methyl group, current 
amphetamine-like SAR would suggest that this compound should be inactive. So, why is MDPV 
present in the “bath salts” mixture? 
        One, relatively obscure, study found that a 20 mg/kg dose of MDPV (41) (i.e., the only dose 
examined) increased the locomotor activity of mice.
183
 The same study also found that MDPV 
can increase striatal levels of DA.
183
 Hence, the possibility exists that MDPV (41) might act at 
the level of the dopamine transporter. This needs to be further examined. Nevertheless, although 
this is a clue that MDPV might be psychoactive, there is certainly no reason to suspect (from a 
structure-activity perspective) that MDPV would ever become a component of a widely used 
drug of abuse (i.e., ‘bath salts’). Given its seemingly low potency (i.e., it was evaluated at a dose 
of 10 times that of methamphetamine),
183
 MDPV might not seem attractive (relative to the 
potency of other central stimulants) for distribution. Certainly, then, there was no obvious reason 
why it should be included with mephedrone as a component of bath salts. 
        Flephedrone (30) is the N-methyl cathinone analog of p-fluoroamphetamine (7). Recently, 
flephedrone abuse has been on an increase
190,191
 and, because it is an analog of methcathinone, 
an agent that acts at the dopamine transporter, it is essential to examine its activity at the 
dopamine transporter as well. 
        Methedrone (33) is the N-methyl analog of 4-methoxycathinone (32). There are some 
deaths reported related to abuse of methedrone (see Introduction). Methedrone is the N-methyl 
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cathinone analog of the Schedule 1 drug 4-methoxyamphetamine (PMA, 11).
201
 Methedrone is 
also the methcathinone analog of p-methoxymethamphetamine (PMMA, 31), which is also a 
drug of abuse. Based on this knowledge regarding methedrone, it is important to study its 
mechanism of action. 
        A major goal of the present investigation will be to prepare mephedrone (27), methedrone 
(33), and flephedrone (30) so that their actions at the hDAT can be evaluated and compared with 
that of methamphetamine (2) and methcathinone (24). Structurally-related amphetamine and 
cathinone analogs (see Figure 3) not currently on-hand will also be synthesized. 
        A related goal is to prepare at least one example of the optical isomers of a cathinone and/or 
methcathinone analog to determine the effect of stereochemistry. 
        Other proposed synthetic targets are (±)amphetamine (1), the individual optical isomers of 
3,4-dichloroamphetamine (43), and S(+)-N-ethylamphetamine. 
 
         Krasnodara Cameron, a graduate student in the De Felice laboratory, obtained the response 
as shown in Figure 4 using different combinations of (+)-amphetamine and (-)-amphetamine. 
The response curve appears to show an anomaly for the 5:5 mixture (i.e., the ‘synthetic’ 
racemate). To resolve the problem, authentic (±)-amphetamine (1) will be synthesized and 
evaluated. 
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Figure 4. Response (normalized current) curve of isomers of amphetamine (1) at different ratios 
generated at the hDAT expressed in frog oocytes.   
 
         The individual optical isomers of 3,4-dichloroamphetamine will be synthesized as a 
precursor for its eventual reduction with tritium gas to obtain tritiated isomers of amphetamine. 
These will be utilized for studying transport mechanisms at the DAT. 
         One of the cathinones reported in Table 5 is ethcathinone (37), which is the N-ethyl 
homolog of cathinone (23). To determine whether the amphetamine analog of ethcathinone (37) 
acts at the DAT, S(+)-N-ethylamphetamine (S(+)44) will be synthesized.   
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         In summary, then, the specific aims of the present study are: 
a) To prepare mephedrone (27), methedrone (33), and flephedrone (30), compounds identified 
in what have been termed ‘bath salts’ for examination at the DAT 
b) To prepare, where necessary, amphetamine and/or methamphetamine analogs related to the 
above compounds for comparison with their cathinone or methcathinone counterparts at the 
DAT. Specifically, the following compounds are considered: 
 
 
Compounds 7, 11, and 31 are already on-hand, so compounds 16, 25, and 28 will be synthesized. 
c) To prepare a pair of optical isomers of a cathinone or methcathinone analogs for      
examination at the DAT to determine the role of stereochemistry. 
d)  To examine the effect of MDPV at the DAT. 
e)  To prepare an authentic sample of racemic amphetamine (1), the individual optical  isomers 
of its 3,4-dichloro counterpart (i.e., 43), and S(+)-N-ethylamphetamine (S(+)44). 
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IV. Results and Discussion 
 
A. SYNTHESIS 
        The various amphetamine and cathinone analogs required for this study were prepared in 
our laboratory. For example, the synthesis of mephedrone (27), methedrone (33) and flephedrone 
(30) are shown in Scheme 1. 
 
Scheme 1. a: Br2, CH2Cl2, N2, rt; b: i) MeNH2 (in 33% ethanol), absolute EtOH 0 °C; ii) 
concentrated HCl 
        Compounds 27, 33, and 30 were prepared based on published procedures for similar 
compounds.
209,210
 4-Methylpropiophenone (45), 4-methoxypropiophenone (46) and 4-
fluoropropiophenone (47) were dissolved in CH2Cl2 and allowed to react with bromine 
individually to afford white solid compounds 48, 49, and 50, respectively. These intermediates 
were treated individually with MeNH2 at 0 °C in absolute EtOH to afford the free base of 
compounds 27, 33, and 30 which, upon treatment with concentrated HCl, resulted in their 
hydrochloride salts. The melting points of compounds 27, 33, and 30 were consistants with their 
reported melting points.
167,211,212 
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        p-Methylamphetamine (16) was prepared following a published procedure for a similar 
compound (i.e., (±)-amphetamine)  (Scheme 2).
213,214
  
 
Scheme 2. a: CH3CH2NO2, n-butylamine, reflux; b: i) LiAlH4, reflux; ii) HCl gas 
        p-Methylbenzaldehyde (51) was allowed to react with nitroethane in the presence of n-
butylamine under reflux for 9 h to afford yellow crystals of p-methylnitrostyrene (52). 
Compound 52 was reduced with LiAlH4 to give the free base of p-methylamphetamine (16) 
which upon treatment with HCl gas, resulted in the hydrochloride salt 16. The melting point of 
compound 16 was consistant with the literature melting point for this compound.
215
   
        p-Methylmethamphetamine (25) was prepared from p-methylamphetamine (16) as shown in 
Scheme 3 based on the reported procedure for a similar compound (i.e., (R)-2-methylamino-1-
phenylpropane).
216 
 
Scheme 3. a: ClCOOCH3, K2CO3, rt; b: i) LiAlH4, reflux; ii) aqueous HBr 
        p-Methylamphetamine (16) was treated with methyl chloroformate in the presence of 
K2CO3 for 1 h at room temperature to give 53. Compound 53 was reduced with LiAlH4 to afford 
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p-methylmethamphetamine as the free base, which was treated with aqueous HBr to afford the 
hydrobromide salt 25. The melting point of compound 25 (mp = 125-128 °C) was not consistant 
with that in the literature (mp = 159 °C);
217
 therefore, the product was further characterized by 
elemental microanalysis for C, H, and N, and instrumental analysis which supported the structure 
of compound 25.  
        p-Fluoromethamphetamine (28) was prepared based on a reported procedure by Fotsch et 
al. (Scheme 4).
218
 
 
Scheme 4. a: i) CH3NH2·HCl, NaBH4, Ti(IV)[OCH(CH3)2]4; ii) HCl gas 
        4-Fluorophenylacetone (54) was reacted with methylamine HCl and titanium (IV) 
isopropoxide in the presence of trimethylamine for 3 h at room temperature to afford the free 
base of p-fluoromethamphetamine (28). The free base was treated with HCl gas to obtain the 
hydrochloride salt 28. The final product, 28, was characterized by elemental microanalysis for C, 
H, and N. 
        Attempts were made to prepare the optical isomers of mephedrone (27). One of the routes, 
shown below in Scheme 5, was based on a published procedure for a similar compound (i.e., (S)-
2-amino-1-(4-methylphenyl)-1-propanone).
219
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 Scheme 5. a: oxalyl chloride: b: AlCl3; c: CF3COOH 
        Compound 56 was prepared by treating Boc-N-methyl-D-alanine (55) with oxalyl chloride. 
Then compound 56 was reacted with toluene using a Lewis acid, AlCl3, as catalyst in an attempt 
to obtain compound 57, but this reaction did not work. A possible explanation for this might be 
that in the presence of the Lewis acid the Boc-protecting group is not stable. So, a different route 
was explored with a different protecting group to overcome this problem. This route (Scheme 6) 
was based on the published procedure for a similar compound (i.e., (S)-2-amino-1-(4-
methylphenyl)-1-propanone).
219 
        Compound 59 was prepared by treating N-methyl-L-alanine (58) with ethyl trifluoroacetate 
in the presence of 1,1,3,3-tetramethylguanidine. Compound 59 was treated with oxalyl chloride 
to obtain compound 60, which upon treatment with toluene in the presence of AlCl3 should give 
compound 61. But, unfortunately, this reaction did not work. This result was not expected and no 
possible explanation can be offered. 
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Scheme 6. a: CF3COOC2H5, 1,1,3,3-tetramethylguanidine; b: oxalyl chloride; c: AlCl3   
             Another attempt is shown in Scheme 7. 
Scheme 7. a: CF3COOC2H5, 1,1,3,3-tetramethylguanidine; b: oxalyl chloride; c: AlCl3; d: 
K2CO3, CH3I 
        Compound 63 was prepared by treating D-alanine with ethyl trifluoroacetate in the presence 
of 1,1,3,3-tetramethylguanidine.
219
 The compound 64 was made by reacting compound 63 with 
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oxalyl chloride.
219
 Friedel Crafts acylation was accomplished using AlCl3 to afford compound 65 
from compound 64 and toluene.
219
 Then compound 65 was treated with CH3I in the presence of 
K2CO3 to obtain compound 66.
220
 Here, optical activity was lost and compound 66 was obtained 
as a racemic mixture. A possible explanation is due to the presence of base the carbonyl group in 
compound 65 undergoes tautomerism which results in the racemic product.  
        A totally different route to prepare the isomers of mephedrone (27) is shown in Scheme 8. 
Scheme 8. a: SOCl2; b: AlCl3; c: CH3NH2 
        Compound 68 was prepared by treating S(-)-2-bromopropionic acid with thionyl chloride.
221
 
Compound 48 was then obtained by reacting compound 68 with toluene in the presence of 
AlCl3.
219
 Compound 48 was not optically active. A possible explanation for this racemization is 
the presence of the Lewis acid which promotes tautomerism which ultimately gives rise to 
racemic product. 
        Because many of the problems encountered in the above reactions seem to be related to the 
Friedel-Crafts acylation step, an attempt was made to prepare a known compound using a 
published procedure. Specifically, we focused on the preparation of optical isomers of p-
methylcathinone (26) using a published route.
219 
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Scheme 9. a: CF3COOC2H5, 1,1,3,3-tetramethylguanidine; b: oxalyl chloride; c: AlCl3; d: 
concentrated HCl, i-PrOH 
        Compound 65 was prepared as mentioned in Scheme 7. Compound 65 was treated with 
concentrated HCl and i-PrOH to give one of the optical isomer of p-methylcathinone (i.e. 
R(+)26). The other isomer of p-methylcathinone (i.e. S(-)26) was obtained by the same synthetic 
scheme. Both optical isomers were characterized by microanalysis of C, H, and N, which 
supported the structure of the products, and optical rotations for the isomers were comparable 
with literature rotations. 
        After attempting many routes to obtain optical isomers of mephedrone (27), finally, we 
succeeded in making the optical isomers of p-methylcathinone (26) which are cathinone analogs 
of mephedrone (27, p-methylmethcathinone).  
        S(+)-N-Ethylamphetamine (S(+)44) was prepared based on a published procedure (Scheme 
10).
222
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Scheme 10. a: (AcO)2O, Na2CO3; b: i)LiAlH4, THF, reflux; ii) HCl gas 
        Compound 69 was obtained by treatment of S(+)-amphetamine (S(+)1) with acetic 
anhydride in the presence of Na2CO3. Compound 69 was reduced with LiAlH4 in THF to give 
S(+)-N-ethylamphetamine which upon treatment with HCl gas gave a yellow solid. The melting 
point of the compound S(+)44 matches the reported melting point,
223
 and the optical rotation is 
consistent with the literature.
224 
        Racemic amphetamine (1) was prepared by same procedure mentioned in Scheme 2. The 
only change was that benzaldehyde was used instead of p-tolualdehyde (Scheme 11).
213,214 
 
Scheme 11. a: CH3CH2NO2, n-butylamine, reflux; b: i) LiAlH4, reflux; ii) HCl gas 
        Racemic amphetamine (1) was obtained as its free base which upon treatment with HCl gas 
gave a white solid. The melting point of racemic amphetamine hydrochloride (1) matched the 
literature melting point.
225 
        Attempted preparation of the individual optical isomers of 3,4-dichloroamphetamine, using 
the same procedure as in Scheme 7,
219
 is shown in Scheme 12. 
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Scheme 12. a: CF3COOC2H5, 1,1,3,3-tetramethylguanidine; b: oxalyl chloride; c: AlCl3 
        Compound 64 was prepared as described in Scheme 7. Compound 64 was treated with 3,4-
dichlorobenzene in the presence of AlCl3 to give compound 72. The reaction gave a product, but 
the yield was very low. Compound 72 was characterized by microanalysis of C, H, and N, which 
supported its structure. 
        The low yield may be due to the presence of two halogen groups on the benzene ring which 
might deactivate the aromatic ring to acylation. 
        As the above route was not very efficient, it was decided to synthesize racemic 3,4-
dichloroamphetamine (43) using the same route shown in Scheme 2,
213,214
 and then resolve it.  
 
Scheme 13. a: CH3CH2NO2, n-butylamine, reflux; b: LiAlH4, reflux 
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       The only difference in Scheme 2 and Scheme 13 is that Scheme 2 uses p-
methybenzaldehyde as starting material while 3,4-dichlorobenzaldehyde was used as staring 
material in Scheme 13. The melting point of 3,4-dichloroamphetamine matched the literature 
melting point. 3,4-Dichloroamphetamine (43) was reacted with N-acetyl-L-leucine to obtain a 
salt.
226
 The salt was recrystallized multiple times from H2O.
226
 But, unfortunately, the isomers of 
3,4-dichloroamphetamine were not obtained. Resolution of 3,4-dichloroamphetamine (43) with 
(-)-O-O’-dibenzoyl-L-tartaric acid,227 using MeOH as solvent was also not useful. Synthesis of 
the isomers was abandoned. 
 
B. ELECTROPHYSIOLOGY: 
                 Xenopus laevis oocytes were surgically harvested and injected with hDAT 
mRNA.
228,229 
Then, the injected oocytes were incubated for a period of 4-6 days in an incubation 
solution. Oocytes were held at -60 mV in a two-electrode voltage clamp system for all assays, 
and maintained in a bath with standard recording solution (120 mM NaCl, 5.4 mM K gluconate, 
1.2 mM Ca gluconate, 15 mL of 0.5 M HEPES). All solutions were prepared in standard 
recording solutions and perfused over the oocytes using a gravity-fed perfusion system once a 
stable baseline was obtained. (Note: Electrophysiological studies were done by Krasnodara 
Cameron, a graduate student in Dr. De Felice Laboratory)
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B n 1.61746 0.4154
 
Figure 5. Dose-response curve for S(-)-methcathinone (S(-)24). 
        Figure 5 shows the dose-response curve of S(-)-methcathinone (S(-)24). Various data points 
were obtained by exposing hDAT-expressing oocytes to different concentrations of the S(-)-
methcathinone (S(-)24) and measuring the peak current. The EC50 value for S(-)-methcathinone 
(S(-)24) was determined to be 0.14 μM. The same method applied to S(+)-methamphetamine 
(S(+)2) provided an EC50 value of 0.56 (±0.08) μM (data not shown). These studies confirmed 
previous findings,
147,230
 using different methods, that S(-)-methcathinone is more potent than 
S(+)-methamphetamine. S(-)-Methcathinone (S(-)24) and S(+)-methamphetamine (S(+)2) will be 
used here as standards for comparing all compounds proposed in the Specific Aims. 
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Figure 6. Dose-response curve for racemic mephedrone (27). 
        A dose-response curve was obtained for (±)-mephedrone (27) (Figure 6) and it was 
determined that the EC50 of (±)-mephedrone (27) is 0.75 μM. It shows that (±)-mephedrone (27) 
has slightly lower potency (EC50=0.75 μM) than S(+)-methamphetamine (EC50=0.56 μM) and 
almost 6-fold lower potency than S(-)-methcathinone (EC50=0.14 μM). Although considering its 
EC50 value is for the racemate, the S-enantiomer of mephedrone might have a potency higher 
than that of S(+)-methamphetamine (S(+)2). This remains to be determined. (±)-Mephedrone 
(27) showed notably lower efficacy (41%) than S(+)-methamphetamine (S(+)2)(102%) but it 
showed comparable efficacy to S(-)-methcathinone (S(-)24)(56%). 
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Figure 7. Current generated in hDAT by application of drugs (10 μM) at -60 mV. All traces 
were normalized to the peak size of S(-)MCAT (S(-)24) and were in the range of 10-20 nA. A. 
S(+)-methamphetamine (S(+)2); B. S(-)-methcathinone (S(-)24); C. (±)-mephedrone (27). 
        
         As shown in Figure 7, (±)-mephedrone (27) as well as S(-)-methcathinone (S(-)24) 
generated depolarizing currents with a sustained leak current (also called a ‘shelf’) that persisted 
even after the drug was removed. Multiple experiments showed that the size of shelf current was 
proportional to the time of exposure and the concentration of the drug (data not shown). It was 
found that the persistent depolarizing current caused by (±)-mephedrone (27) was proportionally 
larger than the shelf current induced by S(+)-methamphetamine (S(+)2) but less pronounced than 
in the case of S(-)-methcathinone (S(-)24). The similarity of the electrophysiological signature of 
(±)-mephedrone (27) to that of S(+)-methamphetamine (S(+)2) suggests that (±)-mephedrone 
(27) shares dopamine-like releasing properties similar to S(+)-methamphetamine (S(+)2). 
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        As mentioned earlier (see Introduction), mephedrone (27) and MDPV (41) are constituents 
of “Bath salts”. It is worth discussing the electrophysiological results of MDPV (41) here. (Note: 
MDPV (41) was synthesized by Dr. R. Kolanos, in Dr. Glennon’s lab). It was found that (±)-
MDPV (41) failed to produce a depolarizing effect similar to that of (±)-mephedrone (27). 
Unlike, (±)-mephedrone (27), (±)-MDPV (41) produced a hyperpolarizing current at hDAT 
similar to that produced by cocaine. 
 
Figure 8. Blockade of hDAT-mediated currents at -60 mV. A) S(+)-amphetamine (S(+)1) is 
blocked by cocaine; B) (±)-mephedrone (27) blocked by cocaine; C) (±)-mephedrone blocked by 
(±)-MDPV (41). Traces were normalized to the peak size of S(-)-methcathinone (Figure 6) and 
were in the range of 10-20 nA. 
         
        The persistent shelf current produced by (±)-mephedrone (27) at hDAT is reversed, 
similarly to the S(+)-amphetamine (S(+)1) shelf reversal, by cocaine (a hDAT blocker) (Figure 
8). The current generated by (±)-mephedrone (27) was also blocked by (±)-MDPV (41), 
suggesting that the (±)-MDPV (41), although structurally similar to other cathinones and very 
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different from cocaine, might represent a new class of cocaine-like hDAT blocker. Preliminary 
data indicated that (±)-MDPV (41) blocks hDAT-mediated current for a significantly longer time 
than cocaine. This action might be responsible for the “strong addicting” properties of (±)-
MDPV (41) reported online by users. 
 
Figure 9. Dose-response curves for S(+)-methamphetamine (S(+)2), S(-)-methcathinone (S(-
)24), (±)-mephedrone (27) and (±)-MDPV (41) in hDAT at -60 mV. In the case of (±)-MDPV 
(41) each drug concentration was applied in the presence of dopamine (5 μM). 
         
        Figure 9 shows the dose-response curves for S(+)-methamphetamine (S(+)2), S(-)-
methcathinone (S(-)24), (±)-mephedrone (27) and (±)-MDPV (41). As mentioned earlier, it can 
be seen in Figure 9 that (±)-mephedrone (27) has notably lower efficacy (41%) than S(+)-
methamphetamine (S(+)2)(102%), but it has comparable efficacy to S(-)-methcathinone (S(-
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)24)(56%). Figure 9 also shows that (±)-MDPV (41) blocking the dopamine produced 
depolarization as mentioned earlier. 
        To conclude, the studies showed that structurally related synthetic cathinones can have 
dissimilar biophysical signatures depending on the feature added to the β-keto amphetamine 
template. “Bath salts” contains both (±)-mephedrone (27) and (±)-MDPV (41) as major 
ingredients. (±)-Mephedrone (27) has the biophysical signature of a dopamine releasing agent 
just like S(+)-methamphetamine (S(+)2) whereas the other synthetic cathinone, (±)-MDPV (41), 
appears to behave as a cocaine-like dopamine reuptake inhibitor. The combination of these two 
mechanisms may account for the severe behavioral toxicity of “bath salts” (see Introduction). 
“Bath salts” are relatively new products to the drug abuse market, hence there is limited 
information about their mechanism of action. The above-mentioned results might be useful in 
prediction of releasing or blocking properties of existing and novel psychoactive drugs as well as 
forecasting the action of next-generation drugs with abuse potential. 
        Just as with (±)-mephedrone (27), the EC50 of (±)-flephedrone (30) was obtained (1.10 μM). 
Studies showed that flephedrone (data not shown) is half as potent as S(-)-methamphetamine 
(EC50=0.56 μM) and 10-fold less potent than S(-)-methcathinone (EC50=0.14 μM). Flephedrone 
(30) was found to produce 65% effect relative to DA. However, the similarity of the 
electrophysiological signature of (±)-flephedrone (30) and S(+)-methamphetamine (S(+)2) 
suggested that (±)-flephedrone (30) shares dopamine-like releasing properties similar to S(+)-
methamphetamine (S(+)2). 
        Methedrone (33) and other amphetamine, methamphetamine, and cathinone analogs 
described in the Specific Aims (compounds: 7, 11, 16, 25, 28, and 31) are currently under 
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investigation. The pair of optical isomers of p-methylcathinone (i.e. S(-)23, and R(+)23) and 
S(+)-N-ethylamphetamine (S(+)44) are also under investigation. 
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Figure 10. Response (normalized current) curve of isomers of amphetamine (1) at different 
ratios compared with the response curve of racemic amphetamine (1).   
        As mentioned in the Specific Aims, the De Felice lab obtained the response curves as 
shown in Figure 4 using different combinations of S(+)-amphetamine (S(+)1) and R(-)-
amphetamine (R(-)1). It appears that an equal mixture of the two isomers produced less of an 
effect than either an 8:2 mixture or a 2:8 mixture. This seemingly aberrant response might be the 
result of weighing error, or a problem associated with the optical purity of one of the isomers. 
(±)-Amphetamine (1) was synthesized and evaluated to resolve the problem. The experiment 
shown as Figure 4 was repeated, but racemic amphetamine (1) was used in place of the 5:5 
mixture (Figure 10). Figure 10 shows that, in fact, the result in Figure 4 is correct and that both 
the actual racemate of amphetamine and the mixture of two isomers gave the same results 
  
76 
 
(within experimental error). But, the question now is why the response of racemate amphetamine 
is less than that of the 8:2 or 2:8 mixtures. Further investigation is required to properly address 
this issue. 
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V. Conclusion 
 
        The most common constituents of ‘bath salts’, mephedrone (27) and MDPV (41), were 
prepared for electrophysiological examination at the hDAT. Methedrone (33) and flephedrone 
(30), which might sometimes appear (amongst other agents) in the ‘bath salts’ combination, were 
also prepared for evaluation. Amphetamine analogs (i.e., p-methylamphetamine (25), and S(+)-
N-ethylamphetamine (S(+)44)), and several methamphetamine analogs (i.e., p-
methylmethamphetamine (25), and p-fluorometh- amphetamine (28)) were synthesized for 
electrophysiological comparison. Optical isomers of p-methylcathinone (26), which is the N-
desmethyl counterpart of mephedrone (27, i.e., p-methylmethcathinone), were synthesized. 
Racemic amphetamine, although well known but not readily available, was synthesized. All 
compounds were synthesized for examination at hDAT.  
        ‘Bath salts’ contains mephedrone (27) and MDPV (41) (see Introduction) as its most 
common constituents; sometimes, other constituents have been identified. Mephedrone was 
prepared and examined at the hDAT. (±)-Mephedrone (27; EC50 = 0.75 μM) was found to be 
slightly lower in potency than S(+)-methamphetamine (EC50 = 0.56 μM), and almost 6-fold lower 
in potency than S(-)-methcathinone (EC50 = 0.14 μM). While (±)-mephedrone (27) displayed 
notably lower efficacy (41%) than S(+)-methamphetamine (S(+)2; 102% relative to DA), it 
showed comparable efficacy to S(-)-methcathinone (S(-)24; 56%). (±)-Mephedrone (27) 
produced an electrophysiological signature similar to that of S(+)-methamphetamine 
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(S(+)2) suggesting that (±)-mephedrone (27) shares the dopamine-like releasing properties of 
S(+)-methamphetamine (S(+)2). Unlike, (±)-mephedrone (27), (±)-MDPV (41) produced a 
hyperpolarizing current at hDAT similar to that produced by cocaine. 
        The EC50 value of (±)-flephedrone (30) was determined to be 1.1 μM. It was found that (±)-
flephedrone (30) is half as potent as S(-)-methamphetamine (EC50 = 0.56 μM) and 10-fold less 
potent than S(-)-methcathinone (EC50 = 0.14 μM). As with (±)-mephedrone (27), (±)-flephedrone 
(30) produced an electrophysiological signature similar to S(+)-methamphetamine (S(+)2) 
suggesting that (±)-flephedrone (30) shares dopamine-like releasing properties of S(+)-
methamphetamine (S(+)2). 
         Methedrone (33), and other amphetamine, methamphetamine, and cathinone analogs 
described in the Specific Aims (compounds: 7, 11, 16, 25, 28, and 31) are currently under 
investigation. The pair of optical isomers of p-methylcathinone (i.e. S(-)23, and R(+)23) and 
S(+)-N-ethylamphetamine (S(+)44) are also under investigation. Preliminary data (data not 
shown) already suggest that methedrone (33) is a dopamine-like releasing agent. 
        It was found that both racemic amphetamine (1) and the 5:5 mixture of the two individual 
optical isomers of amphetamine produce a response less than that of the 8:2 or 2:8 mixture of the 
two individual isomers. A possible explanation would be that the R(-)-amphetamine (R(-)1) 
might be competitively inhibiting the effect of S(+)-amphetamine (S(+)1) at certain 
concentrations. But, further investigation is required to properly address this issue. 
 
The current studies provide the first information about the two major constituents of ‘bath salts’ 
on the hDAT expressed in Xenopus oocytes and set the stage for future investigations. 
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VI. Experimental 
 
A. SYNTHESIS 
        Melting points were taken on a Thomas-Hoover melting point apparatus in glass capillary 
tubes and are uncorrected. 
1
H NMR spectra were recorded with a Varian EM-390 spectrometer 
with tetramethylsilane (TMS) as an internal standard. Peak positions are given in parts per 
million (δ). Infrared spectra were obtained on a Nicolet iS10 FT-IR spectrometer. Optical 
rotations were measured on a Jasco DIP-1000 digital polarimeter. Microanalyses were performed 
by Atlantic Microlab Inc. (Norcross, GA) for the indicated elements and results are within 0.4% 
of calculated values. Chromatographic separations were performed on silica gel columns (Silica 
Gel 60, 220-440 mesh, Sigma-Aldrich). Reactions were monitored by thin-layer chromatography 
(TLC) on silica gel GHLF plates (250 μ, 2.5 x 10 cm; Analtech Inc., Newark, DE). 
 
Amphetamine Hydrochloride (1). Compound 1 was prepared according to a literature 
procedure.
214
 A solution of 1-phenyl-2-nitropropene (71, 1.5 g, 9.2 mmol) in anhydrous THF (9 
mL) was added in a dropwise manner to a suspension of LiAlH4 (1.5 g, 40.4 mmol) in Et2O at 0 
°C (ice-bath). After completion of addition, the mixture was heated at reflux for 2 h and then 
quenched at 0 °C by the dropwise addition of absolute EtOH (1.5 mL), H2O (1.5 mL), and 15% 
aqueous NaOH (1.5 mL). The mixture was filtered and the filtrate was dried (Na2SO4). The 
solvent was removed under reduced pressure to give an oily residue. The residue was dissolved 
in absolute EtOH and saturated with HCl gas to afford a  
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yellow solid. Recrystallization from absolute EtOH/anhydrous Et2O gave 0.3 g (22%) of 1 as 
white crystals: mp 147-150 °C (lit.
225
 mp 147-149 °C); 
1
H-NMR (DMSO-d6: salt) δ 1.1(d, J = 
6.5 Hz, 3H, CH3), 2.65 (dd, J = 13.2, 9.2 Hz, 1H, CH2), 3.05 (dd, J = 13.2, 5.0, 1H, CH2), 3.35-
3.40 (m, 1H, CH), 7.22-7.26 (m, 3H, ArH), 7.33 (t, J = 7.2 Hz, 2H, ArH), 8.17 (br s, 3H, NH3
+
). 
1-(4-Methylphenyl)-2-aminopropane Hydrochloride (16; p-Methylamphetamine HCl). 
Compound 16 was prepared using a literature procedure for a similar compound.
214 
1-(4-
Methylphenyl)-2-nitropropene (52, 1.0 g, 5.6 mmol) in anhydrous THF (6 mL) was added in a 
dropwise manner to a stirred suspension of LiAlH4 (0.9 g, 24.8 mmol) in Et2O (14 mL) at 0 °C 
(ice-bath). After completion of the addition, the mixture was heated at reflux for 2 h and then 
quenched at 0 °C by the dropwise addition of absolute EtOH (0.9 mL), H2O (0.9 mL), and 15% 
aqueous NaOH (0.9 mL). The mixture was filtered and the filtrate was dried (Na2SO4). The 
solvent was removed under reduced pressure to give an oily residue which was dissolved in 
absolute EtOH and saturated with HCl gas to afford a yellow solid. Recrystallization from 
absolute EtOH gave 0.3 g (22%) of 16 as white crystals: mp 157-159 °C (lit.
215
 mp 158-159 °C); 
1
H-NMR (DMSO-d6: salt) δ 1.09 (d, J = 6.5 Hz, 3H, CH3), 2.27 (s, 3H, CH3), 2.61 (dd, J = 13.3, 
9.2 Hz, 1H, CH2), 2.99 (dd, J = 13.3, 5.0 Hz, 1H, CH2), 3.32-3.37 (m, 1H, CH), 7.10-7.15 (m, 
4H, ArH), 8.11 (s, 3H, NH3
+
). 
1-(4-Methylphenyl)-2-methylaminopropane Hydrobromide (25; p-Methylmeth-
amphetamine HBr). Compound 25 was prepared using a literature procedure for a similar 
compound.
216 
N-[1-Methyl-2-(4-methylphenyl)ethyl] methyl carbamate (53, 1.7 g, 8.3 mmol) in 
anhydrous THF (5 mL) was added to a cold (0 °C, ice-bath) suspension of LiAlH4 (0.5 g, 12.4 
mmol) in anhydrous THF (50 mL) at such a rate that the reaction remained under control. After 
addition of the carbamate the reaction mixture was heated at reflux under an N2 atmosphere for 2 
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h. The reaction mixture was cooled to 0 °C and quenched with absolute EtOH (0.5 mL), H2O 
(0.5 mL) and 15% NaOH (0.5 mL). The mixture was allowed to stir for 30 min, filtered, and the 
filtrate was dried (Na2SO4). The solvent was evaporated under reduced pressure to give an oily 
residue which was dissolved in absolute EtOH, and aqueous HBr (48%) was added to pH=1. The 
aqueous solvent was removed under reduced pressure to afford a white solid. Recrystallization 
from absolute EtOH gave 0.9 g (34%) of 25 as white crystals: mp 125-128 °C (lit.
217
 mp 159 
°C); 
1
H NMR (DMSO-d6) δ 1.07 (d,  J = 6.5 Hz, 3H, CH3), 2.28 (s, 3H, CH3), 2.57 (dd, J = 13.1, 
9.8 Hz, 1H, CH2), 2.59 (s, 3H, CH3), 3.08 (dd, J = 13.2, 4.3 Hz, 1H, CH2), 3.34-3.45 (m, 1H, 
CH), 7.12-7.16 (m, 4H, ArH), 8.48 (br s, 2H, NH2
+
). Anal. Calcd (C11H17N·HBr) C, 54.11; H, 
7.43; N, 5.74. Found: C, 54.21; H, 7.44; N, 5.70. 
R(+)-1-(4-Methylphenyl)-2-aminopropan-1-one Hydrochloride (R(+)26; R(+)-p-
Methylcathinone HCl). Compound R(+)26 was prepared using a literature procedure for a 
similar compound.
219
 (R)-N-[2-(4-Methylphenyl)-1-methyl-2-oxoethyl]-2,2,2-trifluoroacetamide 
(R(65), 0.5 g, 2 mmol) was dissolved in i-PrOH (44 mL) and concentrated HCl (33 mL). The 
resulting solution was then stirred at 40 °C for 12 h. The solvent was evaporated under reduced 
pressure, followed by addition of Et2O (15 mL) and i-PrOH (1 mL) to precipitate a white solid. 
Recrystallization from absolute EtOH gave 0.05 g (13%) of R(+)26 as white crystals: mp 220-
225 °C; IR (Diamond): 1682 cm
-1
 (C=O); 
1
H NMR (DMSO-d6) δ  1.42 (d, J = 7.2 Hz, 3H, CH3), 
1.41 (s, 3H, CH3), 5.04-5.09 (m, 1H, CH), 7.40 (d, J = 8.0 Hz, 2H, ArH), 7.96 (d, J = 8.2 Hz, 2H, 
ArH), 8.43 (br s, 3H, NH3
+). [α]28D +34 °, c 1, MeOH. Anal. Calcd (C10H13NO·HCl·0.5H2O) C, 
57.55; H, 7.07; N, 6.71. Found: C, 57.62; H, 6.88; N, 6.58. 
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S(-)-1-(4-Methylphenyl)-2-aminopropan-1-one Hydrochloride (S(-)26; S(-)-p-
Methylcathinone HCl). Compound S(-)26 was prepared according to a literature procedure.
219 
(S)-N-[2-(4-Methylphenyl)-1-methyl-2-oxoethyl]-2,2,2-trifluoroacetamide 
((S)65, 0.5 g, 2 mmol) was dissolved in i-PrOH (44 mL) and concentrated HCl (33 mL). The 
resulting solution was then stirred at 40 °C for 12 h. The solvent was evaporated under reduced 
pressure, followed by addition of Et2O (15 mL) and i-PrOH (1 mL) to precipitate a white solid. 
Recrystallization from absolute EtOH gave 0.1 g (21%) of S(-)26 as white crystals: mp 220-225 
°C (lit.
219
 mp 192-193 °C); IR (Diamond): 1683 cm
-1
 (C=O); 
1
H NMR (DMSO-d6) δ  1.42 (d, J = 
7.2 Hz, 3H, CH3), 1.41 (s, 3H, CH3), 5.04-5.10 (m, 1H, CH), 7.41 (d, J = 8.0 Hz, 2H, ArH), 7.96 
(d, J = 8.2 Hz, 2H, ArH), 8.44 (br s, 3H, NH3
+). [α]28D -36.7 °, c 1, MeOH (lit.
222
 [α]22D -32 °, c 
1.06, MeOH). 
1-(4-Methylphenyl)-2-methylaminopropan-1-one Hydrochloride (27; Mephedrone HCl). 
Compound 27 was prepared using a literature procedure for a similar compound.
210
 A solution of 
2-bromo-(4-methyl)propiophenone (48, 0.5 g, 2.2 mmol) in absolute EtOH (5 mL) was added in 
a dropwise manner to a 33% ethanolic solution of MeNH2 at 0 °C (0.2 g, 5.9 mmol) and the 
reaction mixture was allowed to stir for 3 h. Cold, concentrated HCl was then added very slowly 
along with some finely cracked ice until the mixture became acidic (pH=0). The reaction mixture 
was extracted with Et2O (3 x 15 mL) and 48 (0.3 g) was recovered. The aqueous portion was 
evaporated under reduced pressure to dryness. The residue was extracted several times with fresh 
portions of CHCl3 (3 x 15 mL) and each time the insoluble MeNH2HCl was removed by 
filtration. The solvent was evaporated under reduced pressure to give a white solid. 
Recrystallization from absolute EtOH gave 0.05 g (27%) of 27 as white crystals: mp 230-232 °C 
(lit.
167
 mp 232 °C); IR (Diamond) cm
-1
: 1685 (C=O); 
1
H NMR (DMSO-d6) δ  1.44 (d, J = 7.2 Hz, 
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3H, CH3), 1.41 (s, 3H, CH3), 2.59 (s, 3H, CH3), 5.09-5.14 (m, 1H, CH),  7.42 (d, J = 8.0 Hz, 2H, 
ArH), 7.94 (d, J = 8.3 Hz, 2H, ArH), 9.28 (br s, 2H, NH2
+
). 
1-(4-Fluorophenyl)-2-methylaminopropane Hydrochloride (28; p-Fluorometh-
amphetamine HCl). Compound 28 was prepared according to a literature procedure.
218 
Triethylamine (2.0 g, 20 mmol), MeNH2HCl (1.4 g, 20 mmol) and titanium(IV) isopropoxide 
(5.7 g, 20 mmol) were added to a solution of 4-fluorophenylacetone (54, 1.5 g, 10 mmol) in 
absolute EtOH (15 mL). The solution was allowed to stir for 3 h at room temperature. Then 
NaBH4 (0.6 g, 16 mmol) was added to the reaction mixture and stirring was continued for an 
additional 3 h. Aqueous NH3 was added and the white precipitate was removed by filtration. 
Water was added to the filtrate and the aqueous portion was extracted with CH2Cl2 (3 x 20 mL). 
The combined organic portion was washed with 1 N HCl (3 x 10 mL), the aqueous portions were 
combined and washed with CH2Cl2 (3 x 10 mL). The aqueous portion was basified (1N NaOH to 
bring the pH to 9) and the solution was extracted with CH2Cl2 (3 x 20 mL). The combined 
organic portion was dried (Na2SO4) and filtered. The solvent was evaporated under reduced 
pressure to give an oily residue which was dissolved in absolute EtOH and saturated with HCl 
gas to afford an off-white solid. Recrystallization from absolute EtOH gave 0.4 g (20%) of 28 as 
off-white crystals: mp 110-114 °C; 
1
H NMR (DMSO-d6) δ 1.09 (d,  J = 6.5 Hz, 3H, CH3), 2.55 
(s, 3H, CH3), 2.66 (dd, J = 13.3, 9.9 Hz, 1H, CH2), 3.16 (dd, J = 13.3, 4.2 Hz, 1H, CH2), 3.32-
3.34 (m, 1H, CH), 7.14-7.19 (m, 2H, ArH), 7.29-7.32 (m, 2H, ArH), 9.03 (br s, 2H, NH2
+
). Anal. 
Calcd (C10H14FN·HCl) C, 58.97; H, 7.42; N, 6.88. Found: C, 58.94; H, 7.36; N, 6.82. 
1-(4-Fluorophenyl)-2-methylaminopropan-1-one Hydrochloride (30; Flephedrone HCl). 
Compound 30 was prepared using a literature procedure for a similar compound.
210 
A solution of 
2-bromo-(4-fluoro)propiophenone (50, 3.0 g, 13.0 mmol) in absolute EtOH (30 mL) was added 
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in a dropwise manner to a 33% ethanolic solution of MeNH2 (1.0 g, 32.5 mmol) at 0 °C (ice-
bath) and the reaction mixture was allowed to stir for 12 h. Cold, concentrated HCl was then 
added very slowly along with some finely cracked ice until the mixture was acidic (pH=1). The 
reaction mixture was extracted with Et2O (3 x 15 mL). The aqueous portion was evaporated 
under reduced pressure to dryness. The residue was washed several times with fresh portions of 
CHCl3 (3 x 10 mL). The resultant solid was dissolved in H2O and 1N NaOH was added to the 
solution to pH=9. The solution was extracted with CH2Cl2 (3 x 15 mL). The combined organic 
portion was dried (Na2SO4) and the solvent was removed under reduced pressure to give a 
yellow solid. Recrystallization from absolute EtOH gave 0.05 g (2%) of 30 as yellow crystals: 
mp 225-227 °C (lit.
212
 mp 220-222 °C); IR (Diamond): 1686 cm
-1
 (C=O); 
1
H NMR (DMSO-d6) δ 
1.45 (d, J = 7.2 Hz, 3H, CH3), 2.59 (s, 3H, CH3), 5.14-5.19 (m, 1H, CH),  7.44-7.48 (m, 2H, 
ArH), 8.12-8.16 (m, 2H, ArH), 9.36 (s, 2H, NH2
+
). 
1-(4-Methoxyphenyl)-2-methylaminopropan-1-one Hydrochloride (33; Methedrone HCl). 
Compound 33 was prepared using a literature procedure for a similar compound.
210 
A solution of 
2-bromo-(4-methoxy)propiophenone (49, 3.0 g, 12.3 mmol) in absolute EtOH (30 mL) was 
added in a dropwise manner to a 33% ethanolic solution of MeNH2 (1.0 g, 30.9 mmol) at 0 °C 
(ice-bath) and the reaction mixture was allowed to stir for 12 h. Cold, concentrated HCl was then 
added very slowly along with some finely cracked ice until the mixture was acidic (pH=1). The 
reaction mixture was extracted with Et2O (3 x 15 mL). The aqueous portion was evaporated 
under reduced pressure to dryness. The residue was washed several times with fresh portions of 
CHCl3 (3 x 10 mL). The resultant solid was dissolved in H2O and 1N NaOH was added to the 
solution to pH=9. This soltution was extracted with CH2Cl2 (3 x 15 mL). The combined organic 
portion was dried (Na2SO4) and the solvent was removed under reduced pressure to give a white 
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solid. Recrystallization from absolute EtOH gave 1.3 g (47%) of 33 as white crystals: mp 220-
222 °C (lit.
211
 mp 216 °C); IR (Diamond): 1678 cm
-1
 (C=O); 
1
H NMR (DMSO-d6) δ  1.44 (d, J = 
7.1 Hz, 3H, CH3), 2.57 (s, 3H, CH3), 3.88 (s, 3H, CH3), 5.07-5.13 (m, 1H, CH),  7.12 (d, J = 9.0 
Hz, 2H, ArH), 8.02 (d, J = 9.0 Hz, 2H, ArH), 9.30 (s, 2H, NH2
+
). 
1-(3,4-Dichlorophenyl)-2-aminopropane Hydrochloride (43; 3,4-Dichloro-amphetamine 
HCl). Compound 43 was prepared using a literature procedure for a similar compound.
214 
1-(3,4-
Dichlorophenyl)-2-nitropropene (74, 6.1 g, 26.2 mmol) in anhydrous THF (5 mL) was added in a 
dropwise manner to a stirred suspension of LiAlH4 (4.4 g, 115.4 mmol) in Et2O (50 mL) at 0 °C 
(ice-bath). After completion of the addition, the mixture was heated at reflux for 2 h and then 
quenched at 0 °C by the dropwise addition of absolute EtOH (5 mL), H2O (5 mL), and 15% 
aqueous NaOH (15 mL). The mixture was filtered and the filtrate was dried (Na2SO4). The 
solvent was evaporated under reduced pressure to give an oily residue which was dissolved in 
absolute EtOH and saturated with HCl gas to afford a yellow solid. Recrystallization from 
absolute EtOH gave 2.7 g (42%) of 43 as white crystals: mp 175-178 °C (lit.
231
 mp 188-189 °C); 
1
H-NMR (DMSO-d6: salt) δ 1.16 (d, J = 6.5 Hz, 3H, CH3), 2.77 (dd, J = 13.5, 8 Hz, 1H, CH2), 
3.04 (dd, J = 13.5, 5.9 Hz, 1H, CH2), 3.34-3.46 (m, 1H, CH), 7.29 (dd, J = 8.2, 2 Hz, 1H, ArH), 
7.58 (m, 2H, ArH), 8.26 (s, 3H, NH3
+
). 
S(+)-1-Phenyl-2-ethylaminopropane Hydrochloride (S(+)44; S(+)-N-Ethyl-
amphetamineHCl). Compound S(+)44 was prepared according to a literature procedure.
222
 
S(+)-N-(2-Phenyl-1-methylethyl)acetamide (S(+)69, 1.5 g, 8.5 mmol) in anhydrous THF (20 mL) 
was added to a cold (0 °C, ice-bath) suspension of LiAlH4 (0.5 g, 12.6 mmol) in anhydrous THF 
(8 mL) at such a rate that the reaction remained under control. After addition of amide the 
reaction mixture was heated at reflux under an N2 atmosphere for 15 h. The reaction mixture was 
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cooled at 0 °C and quenched with H2O (0.5 mL), 15% NaOH (0.5 mL) and H2O (1.4 mL). The 
mixture was allowed to stir for 30 min, filtered, and the filtrate was dried (Na2SO4). The solvent 
was evaporated under reduced pressure to give an oily residue, which was dissolved in absolute 
EtOH and saturated with HCl gas to afford a yellow solid. Recrystallization from absolute 
EtOH/anhydrous Et2O gave 0.3 g (18%) of S(+)44 as yellow crystals: mp 147-150 °C (lit.
223
 mp 
141-142 °C); 
1
H NMR (DMSO-d6) δ 1.09 (d,  J = 6.6 Hz, 3H, CH3), 1.24 (t, J = 7.2 Hz, 3H, 
CH3), 2.62 (dd, J = 13.1, 10.4 Hz, 1H, CH2), 2.95-3.04 (m, 2H, CH2), 3.23 (dd, J = 13.1, 3.8 Hz, 
1H, CH2), 3.35-3.40 (m, 1H, CH), 7.24-7.27 (m, 3H, ArH), 7.34 (t, J = 7.4 Hz, 2H, ArH); [α]
24
D 
+14.8 °, c 2, H2O (lit.
224
 [α]25D +17.3 °, c 2, H2O). 
2-Bromo-(4-methyl)propiophenone (48). Compound 48 was prepared according to a literature 
procedure.
209
 4-Methylpropiophenone (45, 4.0 g, 27.0 mmol) and CH2Cl2 (100 mL) were placed 
in a 250 mL flask equipped with a magnetic stir bar. The solution was allowed to stir under an N2 
atmosphere and bromine (4.3 g, 27.0 mmol) was added to the flask. (Note: a small amount of 
bromine was added to initiate the reaction; the color dissipated as the reaction occured. After the 
reaction initiated, the remaining bromine was added over 10 min). A needle was placed in the 
septa to allow the HBr gas that formed in the reaction to escape from the flask. After stirring the 
solution for 12 h, saturated NaHCO3 was added to bring the pH of the mixture to 9. The aqueous 
layer was extracted with CH2Cl2 (3 x 15 mL). The combined organic portion was dried (Na2SO4) 
and the solvent was removed under reduced pressure to give a white solid. Recrystallization from 
absolute EtOH gave 2.7 g (44%) of 48 as white crystals: mp 75-78 °C (lit.
232
 mp 76-77 °C); 
1
H 
NMR (CDCl3) δ 1.90 (d, J = 6.6 Hz, 3H, CH3), 2.42 (s, 3H, CH3), 5-25-5.30 (q, 1H, CH), 7.29 
(d, J = 8.1 Hz, 2H, ArH), 7.92 (d, J = 8.2 Hz, 2H, ArH). 
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2-Bromo-(4-methoxy)propiophenone (49). Compound 49 was prepared using a literature 
procedure for a similar compound.
209 
4-Methoxypropiophenone (46, 4.0 g, 24.4 mmol) and 
CH2Cl2 (100 mL) were placed in a 250 mL flask equipped with a magnetic stir bar. The solution 
was allowed to stir under an N2 atmosphere and bromine (3.9 g, 24.4 mmol) was added to the 
flask. (Note: a small amount of bromine was added to initiate the reaction; the color dissipated as 
the reaction occured. After the reaction initiated, the remaining bromine was added over 10 min.) 
A needle was placed in the septa to allow the HBr gas that formed in the reaction to escape from 
the flask. After stirring the solution for 12 h, saturated NaHCO3 was added to bring the pH of the 
mixture to 9. The aqueous layer was extracted with CH2Cl2 (3 x 15 mL). The combined organic 
portion was dried (Na2SO4) and the solvent was removed under reduced pressure to give a white 
solid. Recrystallization from absolute EtOH gave 4.6 g (78%) of 49 as white crystals: mp 62-64 
°C (lit.
233
 mp 66-69 °C); 
1
H NMR (CDCl3) δ 1.80 (d, J = 9.6 Hz, 3H, CH3), 3.80 (s, 3H, CH3), 5-
16-5.21 (q, 1H, CH), 6.87 (d, J = 8.7 Hz, 2H, ArH), 7.93 (d, J = 8.8 Hz, 2H, ArH). 
2-Bromo-(4-fluoro)propiophenone (50). Compound 50 was prepared using a literature 
procedure for a similar compound.
209 
4-Fluoropropiophenone (47, 4.0 g, 26.3 mmol) and CH2Cl2 
(100 mL) were placed in a 250 mL flask equipped with a magnetic stir bar. The solution was 
allowed to stir under an N2 atmosphere and bromine (4.2 g, 26.3 mmol) was added to the flask. 
(Note: a small amount of bromine was added to initiate the reaction; the color dissipated as the 
reaction occured. After the reaction initiated, the remaining bromine was added over 10 min.) A 
needle was placed in the septa to allow the HBr gas that formed in the reaction to escape from 
the flask. After 12 h, saturated NaHCO3 was added to the stirred solution to pH=9. The aqueous 
layer was extracted with CH2Cl2 (3 x 15 mL). The combined organic portion was dried (Na2SO4) 
and the solvent was removed under reduced pressure to give white solid. Recrystallization from 
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absolute EtOH gave 4.3 g (71%) of 50 as white crystals: mp 33-35 °C (lit.
234
 mp 33-34 °C); 
1
H 
NMR (CDCl3) δ 1.89 (d, J = 6.6 Hz, 3H, CH3), 3.80 , 5-20-5.25 (q, 1H, CH), 7.13-7.17 (m, 2H, 
ArH), 8.04-8.07 (m, 2H, ArH). 
1-(4-Methylphenyl)-2-nitropropene (52). Compound 52 was prepared using a literature 
procedure for a similar compound.
213 
p-Methylbenzaldehyde (51, 5.0 g, 41.6 mmol), nitroethane 
(3.1 g, 41.6 mmol) and n-butylamine (0.2 mL) were added to absolute EtOH (4 mL). The 
solution was heated at reflux for 9 h. On cooling the reaction solution, a heavy, yellow and 
crystalline mass was formed. Recrystallization from absolute EtOH gave 2.1 g (29%) of 52 as 
yellow crystals: mp 45-48 °C (lit.
235
 mp 51.5-52.5 °C): 
1
H NMR (CDCl3) δ 2.41 (s, 3H, CH3), 
2.46 (d, J = 0.6 Hz, 3H, CH3), 7.26 (d, J = 8 Hz, 2H, ArH), 7.35 (d, J = 8.1 Hz, 2H, Ar), 8.08 (s, 
1H, CH). 
N-[1-Methyl-2-(4-methylphenyl)ethyl] methyl carbamate (53). Compound 53 was prepared 
using a literature procedure for a similar compound.
216 
Methyl chloroformate (1.0 g, 10.86 
mmol) was added to a solution of 1-(4-methylphenyl)-2-aminopropane (16, 1.3 g, 8.7 mmol) in 
CH2Cl2 (30 mL) with a vigorous stirring. Then K2CO3 (6.0 g, 43.6 mmol) in H2O (30 mL) was 
added to the reaction mixture and stirring was continued for 1 h. The reaction mixture was 
extracted with CH2Cl2 (3 x 10 mL). The organic portion was combined, dried (Na2SO4) and 
filtered. The solvent was removed under reduced pressure to give 1.7 g (95%) of crude 53 as an 
oil, which was used without further purification for the next step. 
1
H NMR (CDCl3) δ 1.10 (d, J 
= 6.6 Hz, 3H, CH3), 2.32 (s, 3H, CH3), 2.65 (dd, J = 13.5, 7.1 Hz, 1H, CH2), 2.79 (dd, J = 13.3, 
5.3 Hz, 1H, CH2),  3.64 (s, 3H, CH3), 3.82-3.98 (m, 1H, CH), 4.51 (br s, 1H, NH), 7.05-7.13 (m, 
4H, ArH). 
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(R)-N-Methyl-N-[2-chloro-1-methyl-2-oxoethyl]-1,1-dimethylethyl carbamate (56). 
Compound 56 was prepared using a literature procedure for a similar compound.
219 
Oxalyl 
chloride (1.5 g, 11.7 mmol) was added to a stirred suspension of Boc-N-methyl-D-alanine (55, 
1.0 g, 4.9 mmol) in CH2Cl2 (18 mL), cooled to 0 °C (ice-bath) followed by addition of pyridine 
(3 drops). The reaction mixture was allowed to warm gradually to room temperature and was 
further stirred for 8 h. The solvent and excess oxalyl chloride were removed by rotary 
evaporation at 30 °C to afford 1.1 g (100%) of 56 as a colorless oil which was used without 
purification for subsequent reaction. 
(S)-2-(N-Methyl-N-trifluoroacetyl)aminopropanoic Acid (59). Compound 59 was prepared 
using a literature procedure for a similar compound.
219 
1,1,3,3-Tetramethylguanidine (0.5 g, 5.0 
mmol) was added to a suspension of N-methyl-L-alanine (58, 5.0 g, 55 mmol) in MeOH (3 mL). 
After 5 min, ethyl trifluoroacetate (0.9 g, 6.0 mmol) was added and the reaction mixture was 
allowed to stir for 6 h at room temperature. The solvent was evaporated under reduced pressure 
to give an oily residue which was dissolved in H2O (8 mL) and acidified with concentrated HCl 
to pH=1. After stirring for 15 min, the mixture was extracted with EtOAc (3 x 20 mL). The 
combined organic portion was washed with brine (20 mL) and dried (Na2SO4). The solvent was 
evaporated under reduced pressure to give a white solid which was washed with n-hexane (20 
mL) and dried to afford 0.9 g (94%) of 59 as an oil; IR (Diamond): 1682 cm
-1
 (C=O). 
(S)-2-(N-Methyl-N-trifluoroacetyl)aminopropanoyl Chloride (60). Compound 60 was 
prepared using a literature procedure for a similar compound.
219 
Oxalyl chloride (1.4 g, 10.7 
mmol) was added to a stirred suspension of (S)-2-(N-Methyl-N-trifluoroacetyl)aminopropanoic 
acid (59, 0.9 g, 4.5 mmol) in CH2Cl2 (17 mL), at 0 °C (ice-bath); this was followed by addition 
of pyridine (1 drop). The reaction mixture was allowed to warm gradually to room temperature 
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and was further stirred for 8 h. The solvent and excess oxalyl chloride were removed by rotary 
evaporation at 30 °C to afford 1.0 g (100%) of 60 as a colorless oil which was used without 
purification for subsequent reactions. 
(R)-2-(N-Trifluoroacetyl)aminopropanoic Acid ((R)63). Compound (R)63 was prepared using 
a literature procedure for a similar compound.
219 
1,1,3,3-Tetramethylguanidine (8.6 g, 75 mmol) 
was added to a suspension of D-alanine (62, 5.0 g, 55.0 mmol) in MeOH (28 mL). After 5 min, 
ethyl trifluoroacetate (9.9 g, 70.0 mmol) was added and the reaction mixture was allowed to stir 
for 6 h at room temperature. The solvent was evaporated under reduced pressure to give an oily 
residue which was dissolved in H2O (70 mL) and acidified with concentrated HCl to pH=1. After 
stirring for 15 min, the mixture was extracted with EtOAc (3 x 20 mL). The combined organic 
portion was washed with brine (20 mL) and dried (Na2SO4). The solvent was evaporated under 
reduced pressure to give a white solid which was washed with n-hexane (20 mL) and dried to 
afford 9.8 g (94%) of (R)63 as a white solid, sufficiently pure for subsequent use: mp 63-65 °C 
(lit.
236
 mp 70-71 °C); IR (Diamond): 1732 cm
-1
 (C=O). 
(S)-2-(N-Trifluoroacetyl)aminopropanoic Acid ((S)63). Compound (S)63 was prepared 
according to a literature procedure.
219 
1,1,3,3-Tetramethylguanidine (8.6 g, 75.0 mmol) was 
added to a suspension of L-alanine (5.0 g, 55.0 mmol) in MeOH (28 mL). After 5 min, ethyl 
trifluoroacetate (9.9 g, 70.0 mmol) was added and the reaction mixture was allowed to stir for 6 h 
at room temperature. The solvent was evaporated under reduced pressure to give an oily residue 
which was dissolved in H2O (70 mL) and acidified with concentrated HCl to pH=1. After stirring 
for 15 min, the mixture was extracted with EtOAc (3 x 20 mL). The combined organic portion 
was washed with brine (20 mL) and dried (Na2SO4). The solvent was evaporated under reduced 
pressure to give a white solid which was washed with n-hexane (20 mL) and dried to afford 10.0 
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g (96%) of (S)63 as a white solid, sufficiently pure for subsequent use: mp 63-65 °C (lit.
219
 mp 
70-71 °C); IR (Diamond): 1731 cm
-1
 (C=O). 
(R)-2-(N-Trifluoroacetyl)aminopropanoyl Chloride ((R)64). Compound (R)64 was prepared 
using a literature procedure for a similar compound.
219 
Oxalyl chloride (6.4 g, 50.7 mmol) was 
added to a stirred suspension of (R)-2-(N-trifluoroacetyl)aminopropanoic acid ((R)63, 4.0 g, 21.6 
mmol) in CH2Cl2 (80 mL) at 0 °C (ice-bath), followed by addition of pyridine (3 drops). The 
reaction mixture was allowed to warm gradually to room temperature and was further stirred for 
8 h. The solvent and excess oxalyl chloride were removed by rotary evaporation at 30 °C 
afforded 4.4 g (100%) of (R)64 as a colorless oil which was used without purification for 
subsequent reactions. 
(S)-2-(N-Trifluoroacetyl)aminopropanoyl Chloride ((S)64). Compound (S)64 was prepared 
according to a literature procedure.
219 
Oxalyl chloride (4.8 g, 38.0 mmol) was added to a stirred 
suspension of (S)-2-(N-trifluoroacetyl)aminopropanoic acid ((S)63, 3.0 g, 16.2 mmol) in CH2Cl2 
(60 mL) at 0 °C (ice-bath), followed by addition of pyridine (3 drops). The reaction mixture was 
allowed to warm gradually to room temperature and was further stirred for 8 h. The solvent and 
excess oxalyl chloride were removed by rotary evaporation at 30 °C to afford 3.3 g (100%) of 
(S)64 as a colorless oil which was used without purification for subsequent reactions. 
(R)-N-[2-(4-Methylphenyl)-1-methyl-2-oxoethyl]-2,2,2-trifluoroacetamide ((R)65). 
Compound (R)65 was prepared using a literature procedure for a similar compound.
219 
Toluene 
(23.0 g, 251.0 mmol) and AlCl3 (5.8 g, 43.2 mmol) were added to (R)-2-(N-
trifluoroacetyl)aminopropanoyl chloride ((R)64, 4.4 g, 21.6 mmol) at room temperature. The 
reaction mixture was allowed to stir for 18 h and then cooled in an ice-bath and slowly quenched 
with 1N HCl (80 mL). The aqueous layer was extracted with CH2Cl2 (3 x 20 mL) and the organic 
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portions were combined and dried (Na2SO4). The solvent was evaporated under reduced pressure 
to give the crude product as an orange oil which was purified by column chromatography (silica 
gel; hexane/EtOAc; 9.7:0.3) to give 0.9 g (22%) of (R)65 as a white solid: mp 77-78 °C;
 1
H-
NMR (CDCl3) δ 1.52 (d, J = 7.1 Hz, 3H, CH3), 2.45 (s, 3H, CH3), 5.44-5.53 (m, 1H, CH), 7.33 
(d, J = 8.0 Hz, 2H, ArH), 7.61 (s, 1H, NH), 7.88 (d, J = 8.3 Hz, 2H, ArH). 
(S)-N-[2-(4-Methylphenyl)-1-methyl-2-oxoethyl]-2,2,2-trifluoroacetamide ((S)65). 
Compound (S)65 was prepared according to a literature procedure.
219 
Toluene (17.3 g, 188.0 
mmol) and AlCl3 (4.3 g, 32.4 mmol) were added to (S)-2-(N-trifluoroacetyl)aminopropanoyl 
chloride ((S)64, 3.3 g, 16.2 mmol) at room temperature. The reaction mixture was allowed to stir 
for 18 h and, then cooled in an ice-bath and slowly quenched with 1N HCl (60 mL). The aqueous 
layer was extracted with CH2Cl2 (3 x 20 mL) and the organic portions were combined and dried 
(Na2SO4). The solvent was evaporated under reduced pressure to give the crude product as an 
orange oil which was purified by column chromatography (silica gel; hexane/EtOAc; 9.7:0.3) to 
give 0.7 g (17%) of (S)65 as a white solid: mp 77-78 °C (lit.
219
 mp 77-78 °C);
 1
H-NMR (CDCl3) 
δ 1.52 (d, J = 7.2 Hz, 3H, CH3), 2.45 (s, 3H, CH3), 5.46-5.53 (m, 1H, CH), 7.33 (d, J = 8.0 Hz, 
2H, ArH), 7.61 (s, 1H, NH), 7.88 (d, J = 8.3 Hz, 2H, ArH). 
N-Methyl-N-[2-(4-methylphenyl)-1-methyl-2-oxoethyl]-2,2,2-trifluoroacetamide (66). 
Compound 66 was prepared using a literature procedure for a similar compound.
220
 (S)-N-[2-(4-
Methylphenyl)-1-methyl-2-oxoethyl]-2,2,2-trifluoroacetamide (65, 1.4 g, 5.4 mmol) was 
dissolved in dry acetone (30 mL), and to that anhydrous K2CO3 (1.5 g, 10.9 mmol) and CH3I (3.1 
g, 21.8 mmol) were added. The reaction mixture was heated at reflux for 48 h. The solvent was 
removed under reduced pressure and the residue was dissolved in H2O (3 mL). The aqueous 
layer was extracted with Et2O (3 x 20 mL) and the organic portions were combined and dried 
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(Na2SO4). The solvent was evaporated under reduced pressure to give the crude product as an oil 
which was purified by column chromatography (silica gel; hexane/EtOAc; 9.9:0.1) to give 1.4 g 
(94%) of 66 as a colorless oil;
 1
H-NMR (CDCl3) δ 1.44 (d, J = 7 Hz, 3H, CH3), 2.41 (s, 3H, 
CH3), 2.96 (s, 3H, CH3), 5.97-6.02 (m, 1H, CH), 7.27 (d, J = 7 Hz, 2H, ArH, 7.83 (d, J = 8.3 Hz, 
2H, ArH). 
(S)-N-(2-Phenyl-1-methylethyl)acetamide (69). Compound 69 was prepared according to a 
literature procedure.
222 
Acetic anhydride (2.1 mL, 22.2 mmol) was added to a stirred suspension 
of Na2CO3 (7.8 g, 73.9 mmol) and S(+)-amphetamine hemisulfate (S(+)1, 3.4 g, 9.3 mmol) in 
H2O (22 mL) at 0 °C (ice-bath). The suspension was allowed to stir for 5 h at room temperature, 
and then extracted with CHCl3 (3 x 20 mL); the combined organic portion was washed with H2O 
(3 x 10 mL) and dried (Na2SO4). The solvent was evaporated under reduced pressure to give a 
white solid. Recrystallization from i-PrOH gave 2.5 g (76%) of 69 as white crystals: mp 121-123 
°C (lit.
222
 mp 121-124 °C); 
1
H NMR (CDCl3) δ 1.09 (d, J = 6.7 Hz, 3H, CH3), 1.92 (s, 3H, CH3), 
2.71 (dd, J = 13.5, 7.1 Hz, 1H, CH2), 2.82 (dd, J = 13.5, 5.7 Hz, 1H, CH2),  4.22-4.29 (m, 1H, 
CH), 5.22 (br s, 1H, NH), 7.16 (d, J = 6.8 Hz, 2H, ArH), 7.17-7.29 (m, 3H, ArH). 
1-Phenyl-2-nitropropene (71). Compound 71 was prepared according to a literature 
procedure.
213 
Benzaldehyde (70, 2.0 g, 18.8 mmol), nitroethane (1.4 g, 18.8 mmol) and n-
butylamine (0.1 mL) were added to absolute EtOH (1.9 mL). The solution was heated at reflux 
for 9 h. On cooling the reaction solution, a heavy, yellow and crystalline mass was formed. 
Recrystallization from absolute EtOH gave 1.1 g (36%) of 71 as yellow crystals: mp 61-62 °C 
(lit.
113
 mp 65 °C); 
1
H NMR (CDCl3) δ 2.27 (d, J = 1.0 Hz, 3H, CH3), 7.23-7.29 (m, 5H, ArH), 
7.90 (s, 1H, CH). 
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(R)-N-[2-(3,4-Dichlorophenyl)-1-methyl-2-oxoethyl]-2,2,2-trifluoroacetamide (72). 
Compound 72 was prepared using a literature procedure for a similar compound.
219 
3,4-
Dichlorobenzene (19.1 g, 129.6 mmol) and AlCl3 (4.3 g, 32.4 mmol) were added to (R)-2-(N-
trifluoroacetyl)aminopropanoyl chloride ((R)64, 3.3 g, 16.2 mmol) at room temperature. The 
reaction mixture was allowed to stir for 18 h and then cooled in an ice-bath and slowly quenched 
with 1N HCl (80 mL). The aqueous layer was extracted with CH2Cl2 (3 x 20 mL) and the organic 
portions were combined and dried (Na2SO4). The solvent was evaporated under reduced pressure 
to give the crude product as an oil which upon standing for 2 days gave 0.01 g (0.2%) of 72 as a 
white solid;
 1
H-NMR (CDCl3) δ 1.52 (d, 3H, CH3), 5.30 (s, 1H, NH), 5.42-5.49 (q, 1H, CH), 
7.79 (d, J = 2 Hz, 1H, ArH), 7.81 (d, J = 2 Hz, 1H, ArH), 8.07 (s, 1H, ArH). Anal. Calcd 
(C11H8Cl2F3NO2·0.25H2O) C, 41.47; H, 2.69; N, 4.40. Found: C, 41.06; H, 2.36; N, 4.27.                                                                                                  
1-(3,4-Dichlorophenyl)-2-nitropropene (74). Compound 74 was prepared using a literature 
procedure for a similar compound.
213 
3,4-Dichlorobenzaldehyde (73, 5.0 g, 28.6 mmol), 
nitroethane (2.1 g, 28.6 mmol) and n-butylamine (0.1 mL) were added to absolute EtOH (3 mL). 
The solution was heated at reflux for 9 h. On cooling the reaction solution, a heavy, yellow and 
crystalline mass was formed. Recrystallization from absolute EtOH gave 4.0 g (61%) of 74 as 
yellow crystals: mp 70-72 °C (lit.
237
 mp 81 °C): 
1
H NMR (CDCl3) δ 0.07 (s, H, CH), 2.43 (d, 3H, 
CH3), 7.96 (s, 1H, ArH), 7.51-7.54 (m, 1H, ArH), 7.24-7.27 (m, 1H, ArH). 
 
B. ELECTROPHYSIOLOGY: 
        Xenopus laevis oocytes were harvested and prepared using Xenopus laevis females.
228,229
 
Oocytes from stage V-VI were selected for cRNA injection within 24 hours of isolation. The 
pOTV vector was used to transcribe cRNA using mMessage Machine T7 kit (Ambion Inc., 
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Austin, TX). Each oocyte was injected with 50 nL of 1 μg/μL hDAT cRNA and was incubated in 
Ringers solution supplemented with Na
+
 pyruvate (550 μg/mL), tetracycline (50 μg/mL), and 5% 
dialyzed horse serum. In all assays, oocytes were held at -60 mV in a two-electrode voltage 
system and maintained in a bath containing standard recording solution (120 mM NaCl, 5.4 mM 
K gluconate, 1.2 mM Ca gluconate, 15 mL of 0.5 M HEPES). In all assays measuring EC50, 
compound’s concentrations were varied depending on the response observed. Each concentration 
point was confirmed by at least three different oocytes measurements. In the recording, 
dopamine was perfused for 30 sec followed by the drug application which was applied for 1 min. 
The drug response was always represented as a percent of dopamine response as a normalization 
measure. Using Clampfit, raw traces were filtered and values for the dopamine and the drug 
induced responses were obtained for an analysis in Origin 8, y=Vmax*x^n/(k^n+x^n). (Note: 
Electrophysiological studies were done by Krasnodara Cameron, a graduate student in Dr. De 
Felice Laboratory) 
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